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Abstract 
Introduction: Bone metabolism is regulated by the Wnt signaling pathway and is 
considered to be crucial for skeletal development. There are two glycoproteins that 
inhibit Wnt function and bone metabolism: sclerostin and Dickkopf-1 (DKK-1). These 
are novel markers of bone metabolism and could be considered valuable tools to 
investigate the mechanisms of bone remodeling. Although the mechanism of the Wnt 
signaling pathway and its inhibitors on bone biology has been well studied, only sparse 
data are available in humans, especially related to age and physical activity differences 
in circulating levels of sclerostin and DKK-1. 
Purpose: The primary purpose of this study was to compare serum concentrations of 
sclerostin and DKK-1 in young and middle-aged premenopausal women. These age 
groups were selected to allow comparisons between women who are still accruing bone 
mass versus those who have already achieved their peak bone mass. The present study 
also evaluated the differences in sclerostin and DKK-1 concentrations based on physical 
activity status {low, moderate, and health enhancing physical activity (HEPA-
active)}.This study further analyzed the relationship between bone density variables, 
jump trials and leg strength with the serum concentrations of sclerostin and DKK-1.  
Methods: In this non-randomized cross-sectional research design, a total of 50 young 
(n=25) and middle-aged (n=25) women participated and completed all protocols. 
During the first visit, participants completed informed consent and HIPAA forms, and 
questionnaires on physical activity, calcium intake, and menstrual history. During the 
second visit, a blood sample was drawn to measure serum levels of sclerostin, DKK-1 
and follicle-stimulating hormone (FSH). Participants’ body composition (percent body 
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fat, fat mass, fat-free mass and bone-free lean body mass), areal bone mineral density 
(aBMD), and bone mineral content ( BMC) of total body, lumbar spine, and dual 
proximal femur was measured with Dual Energy X-ray Absorptiometry (DXA). 
Participants’ non-dominant tibia (4%, 38%, and 66% sites) was measured with 
peripheral Quantitative Computed Tomography (pQCT).  Lower body strength and 
power were assessed by a two-leg press maximal strength test (1RM) and a vertical 
jump test. 
Results: Sclerostin levels were significantly lower in young women compared to 
middle-aged women (p<0.001). No significant age group and physical activity 
differences were observed for DKK-1 levels. Sclerostin levels were significantly higher 
in HEPA-active women compared to low-moderately active women (p<0.05). 
Sclerostin was significantly but weakly positively related with spine L1-L4 aBMD, 
spine L1-L4 Z-Score, several hip aBMD variables, specifically, right neck Z-Score, left 
neck Z-Score, right trochanter BMD, right trochanter Z-Score, left trochanter Z-score 
and total hip right aBMD. DKK-1 also weakly positively related with spine L1-L4 
aBMD, spine L1-L4 Z-Score, right and left trochanter aBMD, and right and left 
trochanter Z-Scores. There was a significant moderate positive relationship between 
sclerostin and cortical vBMD at 38% tibia. The correlations ranged from (r=0.24 to 
0.50; p <0.05). There were significant but small negative associations (r=0.27, p<0.05) 
between time in air and vertical jump height with sclerostin levels.  
Conclusions: Sclerostin concentrations were significantly higher in the middle-aged 
women, which supports a potential role for sclerostin in age-related bone health. The 
results from the current study found higher sclerostin concentrations in women 
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participating in a high volume of physical activity. Age group and physical activity 
status were associated with higher serum sclerostin levels.  Although Wnt signaling 
inhibitors are the negative regulator of bone mass, the findings of a low positive 
association between sclerostin/DKK-1 with BMD were unexpected. Further, the current 
findings may provide preliminary data for future research on exercise interventions and 
Wnt signaling inhibitors.
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Chapter 1: Introduction 
In the early 19th century, a distinguished English surgeon, Sir Astley Cooper, 
described osteoporosis as, “the lightness and softness that (bones) acquire in the more 
stages of life”… this state of bone favors much the production of fracture.” Although 
the osteoporosis concept was previously investigated during the 1770’s by John Hunter, 
the term “postmenopausal osteoporosis” was coined only in 1940. Subsequently, the 
concept of osteoporosis has come to reflect a continuum, where several pathogenic 
mechanisms are associated with loss of bone mass and microarchitectural deterioration 
of bone mass. According to the World Health Organization (WHO, 1994), osteoporosis 
is defined as a systemic skeletal disease and is characterized by increased bone fragility 
and a consequent increase in fracture risk. It has been reported that osteoporosis 
accounts for one of the ten most common diseases, affecting approximately 10 million 
individuals in the United States. It has also been estimated that every year 1.6 million 
hip fractures occur, which could increase from 4.5 million to 6.3 million by the year 
2050. Therefore, the impact of osteoporosis is associated with significant burden on an 
individual’s quality of life and to the society (Cooper, 1992; Gusi, 2006; Lane, 2006). 
Bone mineral density (BMD) is considered a surrogate measure of bone strength 
as 75-80% of bone strength comes from BMD (Arnaud, 1996; Baran, 1999). Therefore, 
loss of BMD is associated with loss of bone strength that leads to increased risk for 
fracture. It has been widely accepted that at any age, the amount of bone mass reflects 
the post-natal bone growth from birth to adulthood. Therefore, achieving high peak 
bone mass in early life is important in predicting lower fracture risk in later life (Khosla, 
2013).  
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The clinical diagnosis of osteoporosis and related fracture is determined by dual-
energy X-ray absorptiometry (DXA). DXA measures areal bone mineral density 
(aBMD), bone mineral content (BMC) at specific sites in the body. Further, the 
diagnosis of osteoporosis is based on comparing the young adult reference population, 
if the T-score or number of standard deviations from the reference population mean is -
2.5 or lower, then the postmenopausal woman is considered to have osteoporosis 
(Kanis, 1994). 
Bone is a dynamic tissue that undergoes continuous remodeling by the process 
of bone resorption and bone formation via osteoclasts and osteoblasts, respectively 
(Robling and Turner, 2006). The remodeling process starts with osteocytes sensing the 
changes in fluid pressure within the bone, which is a response to mechanical loading. 
The entire coupling process of resorption and formation can take 3-6 months to 
complete and occurs at the endosteal surface of the bone (Arnaud, 1996). The bone 
remodeling process is fine-tuned by parathyroid hormone (PTH), calcitonin and sex 
steroid hormones (Eriksen, 2010). Hormones related to calcium homeostasis can 
influence osteoblast and osteoclast activity. The decrease in serum calcium levels is 
associated with the secretion of PTH and vitamin D, which stimulates osteoclast 
activity. Calcitonin is then released in response to increased calcium levels, which will 
inhibit osteoclast activity by stimulating osteoblast activity.  
It has been well-established that exercise plays an important role in preventing 
the loss of bone mass. According to Wolff’s law, skeletal function changes based on the  
increased or decreased demands of mechanical loading. Further, Frost (1997) expanded 
this concept by adding that muscle mass and muscle contraction are required to generate 
3 
mechanical loading. Therefore, load bearing or high impact exercise will stimulate 
mechanical stress above the threshold, an important process for bone formation. 
Mechanotransduction is considered as the predominant mechanism explaining the 
influence of exercise on bone health via mechanical stimuli. However, the exact 
mechanism describing how bone cells detect the mechanical stimuli and control the 
remodeling process of bone is not clearly understood. 
The discovery of the wingless-related integration site (Wnt) signaling pathway 
provides insight to osteoporosis as well as other skeletal diseases. Wnt is comprised of a 
family of secreted signaling glycoproteins, which are important for cell proliferation, 
differentiation, and apoptosis during embryonic development and postnatal bone growth 
(Kikuchi, 2009). The signal provided by Wnt receptors activates the β-catenin pathway, 
which further regulates the expression of Wnt target genes (Clevers, 2012). Several 
glycoproteins that act as Wnt inhibitors fine-tune the Wnt signaling pathway include 
sclerostin and Dickkopf related protein-1 (DKK-1). Findings from animal models have 
suggested that the activation of the Wnt signaling pathway influences the expansion of 
osteoprogenitors, leading to an increase in bone formation. However, Wnt inhibitors, 
such as sclerostin and DKK-1 secreted by osteocytes, can inhibit the signaling pathway 
by binding to the lipoprotein receptor-related protein5/6 (LRP5/6) (Manolagas, 2014).  
The inhibition of sclerostin and DKK-1 provides a promising approach to 
preventing the loss of bone mass. Exercise involving high impact loading has provided 
useful insight into gaining bone mass and muscular strength, compared to unloading or 
sedentary behavior among healthy individuals. Although DXA is the gold standard for 
the diagnosis of osteoporosis based on aBMD, this variable is only a surrogate measure 
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of bone strength. Therefore, the use osteocyte markers such as sclerostin and DKK-1 
could provide crucial information for finding risk for fractures (Zagrodna et al., 2016).  
 It has been well established that mechanical loading reduces the osteocytes’ 
expression of sclerostin, and thus upregulates the Wnt signaling pathway, enhancing the 
process of bone formation (Frost, 1999; Klein-Nulend, 2013).  Both in human and 
animal models, mechanical loading is considered a crucial modulator for bone 
adaptation. Exercise appears to positively influence both areal and cortical and 
trabecular bone formation, especially in premenopausal women (Manolagas, 2014). 
Despite the growing knowledge of the biology of the Wnt/β-catenin pathway 
and its regulation by sclerostin and DKK-1, sparse data are available addressing the 
importance of physical activity and the body’s response to those regulators. Modder et 
al. (2011) reported on the circulating sclerostin levels in a large population-based study 
and found that sclerostin levels were significantly higher with aging in both men and 
women. Similarly, Amrien et al. (2012) conducted a study in healthy adult men and 
women examining sclerostin levels in relation to physical activity and found that men 
had significantly higher sclerostin levels than women and physically active individuals 
had significantly lower sclerostin levels. However, no data are currently available on the 
influence of physical activity on sclerostin and DKK-1 in young adult women. Also, 
growing evidence suggests that increased acceleration during muscle contraction 
provides mechanical forces to stimulate osteogenesis. Only sparse data are available 
that address neuromuscular performance and sclerostin levels (Macias et al., 2012; 
Mosti et al., 2015).  
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Purpose 
The primary purposes of this study were to: (1) Compare serum concentrations 
of sclerostin and DKK-1 in young (20-30 years) and middle-aged (35-45 years) 
premenopausal women. These age groups were selected to allow comparisons between 
women who are still accruing bone mass versus those who have already achieved their 
peak bone mass. (2) Evaluate the differences in sclerostin and DKK-1 concentrations 
based on physical activity status: low, moderate, and health-enhancing physical activity 
(HEPA-active). The secondary purposes of this study were to: (1) Evaluate sclerostin 
and DKK-1 relationships with aBMD and volumetric bone mineral density (vBMD) in 
young and middle-aged premenopausal women; (2) Evaluate sclerostin and DKK-1 
relationships with leg strength; and (3) Evaluate sclerostin and DKK-1 relationships 
with jump power.  
Research Questions  
1. Is there a significant difference in sclerostin and DKK-1 serum concentrations 
between the two age groups of young (20-30 years) and middle-aged premenopausal 
women (35-45 years)? 
2. Is there a significant difference in sclerostin and DKK-1 serum concentrations based 
on the physical activity status (low, moderate, and HEPA-active)?  
3. Is there a significant interaction between age groups (20-30 years and 35-45 years) 
and physical activity status (low, moderate, and HEPA-active) for sclerostin and 
DKK-1 serum concentrations?  
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Hypotheses 
1. Sclerostin and DKK-1 serum concentrations will be lower in young women (20-30 
years) compared to middle-aged premenopausal women (35-45 years). 
2. Women with higher physical activity levels will have lower sclerostin and DKK-1 
serum concentrations.  
3. There will be no interaction between age and activity, as both age groups will show 
the same pattern for sclerostin and DKK-1 serum concentrations, which will 
decrease as physical activity levels (low, moderate, HEPA-active) increase.  
Sub-questions 
1. Is there a relationship between sclerostin and DKK-1 serum concentrations and 
aBMD and vBMD in young and middle-aged premenopausal women?  
2. Is there a relationship between sclerostin and DKK-1 serum concentrations and 
jump power and leg strength in young and middle-aged premenopausal women? 
Sub-hypotheses 
1. There will be a moderate inverse relationship between sclerostin and DKK-1 serum 
concentrations with aBMD and vBMD in young and middle-aged premenopausal 
women. 
2. There will be a strong inverse relationship between sclerostin and DKK-1 serum 
concentrations with jump power and leg press in young and middle-aged 
premenopausal women. 
Significance of the study  
Due to the paucity of data in the literature, the present study aimed to investigate 
the levels of sclerostin and DKK-1 in young and middle-aged women (20-30 yrs and 
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35-45 years). Wnt signaling is crucial in bone development, which can affect peak bone 
mass. Sclerostin and DKK-1 are potent regulators of the Wnt signaling pathway, which 
directly bind to Wnt ligands and suppress gene transcription for bone formation.  
To date, no study has examined Wnt inhibitors in young and middle-aged 
population and its association with areal and volumetric bone densities. Therefore, the 
present study aimed to compare two Wnt signaling inhibitors to understand the bone 
biology in young versus middle-aged premenopausal women. The selection of these age 
groups allowed comparisons between women who are still accruing bone mass versus 
those who have already achieved their peak bone mass. The understanding of Wnt 
signaling pathway utilized by sclerostin and DKK-1 is still incomplete and measuring 
those Wnt signaling inhibitors could be helpful to determine the mechanism of peak 
bone mass and mechanical loading in bone metabolism. 
Assumptions 
1. Participants were honest and accurate while completing the health screening 
questionnaire and other questionnaires. 
2. Participants were fasted overnight and well hydrated during the time of blood 
collection. 
3. Participants gave maximum effort during 1RM testing. 
4. Participants gave maximum effort for each jump trial. 
Delimitations 
1. This study included healthy women between ages 20-30 years and 35-45 years old.  
2. All the participants were from University of Oklahoma, Norman and surrounding 
areas. 
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3. Participants with metal implants in spine or hip were excluded from this study. 
Limitations 
1. Participants who participate in this study were volunteers, and thus may not 
accurately represent different sub-populations within young and middle-aged 
premenopausal women. 
2. This study was designed as cross-sectional study; hence cause-effect cannot be 
determined. 
3. Extrinsic factors such as dietary intake and genetics were not controlled. 
Operational Definitions  
1. 1 Repetition Maximum (1-RM) Test: The maximum amount of weight that can be 
lifted by the individual one time throughout the full range of motion with correct 
technique (Harter, 1990). 
2. Areal BMD: The bone mineral content in one square centimeter of bone and is 
measured in gm/cm2 (Bouxein, 2008). 
3. Bone Mineral Content: The amount of measured bone mineral in grams (Nattiv et 
al., 2007). 
4. Bucking Ratio: It is ratio of the outer cortex to the cortical thickness and reflect the 
strength parameter of hip structural analyses. Buckling ratio greater than 10 reflects 
significant loss of strength (Choui, 2016). 
5. Cortical bone: Compact, highly calcified (~90%) bone, predominantly found in the 
diaphysis of long bones (Burr and Allen, 2014). 
6. Cross-sectional moment of inertia: It is the bending stress that occur from neutral or 
centroid axis (Beck, 2007). 
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7. Dual–energy x-ray absorptiometry (DXA): the most widely used method in 
assessing bone mineral content and body composition in adults and children that 
utilizes low doses of ionizing radiation and provides precise results in the 
assessment of bone mineral content and body composition in adults and children 
(Blake, 2013). 
8. Jump Power: The measurement of vertical jump against an individual’s center of 
gravity by elevating off the ground from the standstill position in the assessment of 
neuromuscular performance (Buehring, 2010). 
9. Mechanical Loading: The use of skeletal muscle to overpower a set force by 
stressing the bone at the specific bone site (Frost, 1997). 
10. Mechanotransduction: Detection and response of the bone cell to mechanical 
loading (Turner, 1998). 
11. Osteoblast: Type of bone cell responsible for bone formation (Marcus et al., 2013). 
12. Osteoclast: Type of bone cell responsible for bone resorption (Marcus et al., 2013). 
13. Osteocyte: Type of bone cell responsible for mechanotransduction (Bonewald, 
2011). 
14. Osteopenia: Normal loss of bone mass with aging and is determined by a BMD T-
score between 1 and  2.5 standard deviations below the young adult mean (T-scores 
-1.1 to -2.4) (Kanis, 1994). 
15. Osteoporosis: A condition when aBMD is ≤ 2.5 SD below compared to Caucasian 
young adult reference population (T-score ≤ 2.5) (Kanis, 1994).  
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16. Peripheral Quantitative Computed Tomography (pQCT): An imaging technique that 
assesses volumetric BMD (vBMD), bone geometry and strength of total bone, 
cortical and trabecular bone of peripheral limbs (Blew et al., 2014). 
17. Premenopausal women: Women with no signs of menopause, have all of their 
reproductive organs and have a regular menstrual cycle most months of the year 
(Kremer, 2009). 
18. Stress-Strain Index (SSI): A cortical density-weighted section modulus of bone, 
which gives a measure of bending and torsional strength of the diaphyseal sites in 
bone (Cointry, 2014). 
19. Sectional Modulus (SM): SM reflects the strength parameter according to cross-
sectional moment of inertia that occurs at the furthest point from the neutral axis 
(Choui, 2016).  
20. Strength Index (SI): It is the measure of hip ability to withstand a fall at the greater 
trochanter site (Faulkner et al., 2006). 
21. Trabecular Bone: Bone that is found at the ends of long bones, in the lumbar spine 
and intertrochanteric area of the femur, and that is comprised of the loosely 
organized porous matrix with high metabolic characteristics (Blew et al., 2014).  
22. Volumetric bone mineral density (vBMD): The amount of bone mineral (mg) in a 
cubic centimeter of bone (Hind, 2007). 
23. Wnt signaling: A signal transduction pathway where Wnt binding leads to the 




Chapter 2: Review of Literature 
The mechanosensory and mechanoresponsive processes in living organisms 
have provided critical cues in understanding the growth and development of the skeletal 
system in human beings (Ingber, 2005). Bone is an adaptable tissue that can respond to 
the strain imposed by mechanical loading, which is important for the development of 
bone strength.  
During the nineteenth century, Julius Wolff proposed that the stress placed on a 
bone is the major determinant of the bone's architecture and stated that bone possesses 
the property of functional adaptation. Bone architecture and mass are adaptable to the 
demands of the mechanical stress placed upon the skeleton (Turner, 1998). Later, Frost 
expanded upon Wolff’s idea and introduced the mechanostat theory, which postulated 
that a mechanical threshold can control the formation and removal of bone mass from 
the skeleton. Frost proposed that below a specific threshold of mechanical loading, bone 
resorption would occur, and above this threshold; when greater peak load is applied 
bone formation occurs, resulting in the increased bone strength (Frost, 2000).  
Bone adaptation to mechanical loading suggests that bone strength is plastic and 
can be modulated in adults. Bone adaptation is driven by the processes of activation, 
resorption and formation (Burr, 2014) modeling and remodeling. Further, with 
experimental evidence, Turner developed the concept of three fundamental rules for 
bone adaptation: 1) Bone adaptation is driven by dynamic loading; 2) a short duration of 
mechanical loading is effective for an adaptive response; and  3) bone cells 
accommodate and become less responsive with routine mechanical loading (Turner, 
1998). Therefore, the adaptive nature of the skeleton provides evidence of the 
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phenotypic influence of mechanical loading, with diminished physical signals resulting 
in the onset of loss of bone and muscle mass (Ozcivici et al., 2010). Although the exact 
mechanism of bone adaptation is not clearly understood, the basics of bone physiology 
and various biochemical events that take place during the bone modeling and 
remodeling processes can provide some information regarding bone adaptation. 
Understanding bone turnover could provide crucial information about how dynamic 
tissue undergoes resorption or formation. Bone turnover is the coupled process that is 
carried by osteoblasts, the bone forming cells, and osteoclasts, the bone resorption cells. 
Osteoblasts and osteoclasts differ in morphological and biochemical properties and, in 
humans, by-products of these markers have been widely used clinically by measuring 
them in serum, saliva or urine. 
According to the Roux principle (Roux, 1895), bone adaptation is achieved 
under the influence of a cellular process where the signal for the initiation of bone 
formation is transmitted via mechanotransduction. Recently, exploring the role of 
osteocytes have gained attention among researchers. One hypothesis suggested that 
mechanotransduction can be carried out via fluid flow over the osteocytes and 
cytoskeleton adhesion protein, which are important for the amplification of the strain 
(Han et al., 2004; Turner, 1998). Another hypothesis postulated by Bell et al. (2008) 
suggested that an anatomical structure of osteocytes, the cilium, is able to sense the 
hydrostatic pressure generated by the mechanical loading. There has been considerable 
progress made to identify the key players in mechanotransduction, of which inhibition 
of SOST and DKK-1 expression are the most important. It has been well accepted that 
Wnt pathways transmit mechanical signals in the bone remodeling process via 
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activation and inactivation of signaling cascades (Klein-Nulend, 2013). Data from 
animal models have suggested that the absence of mechanical loading leads to an 
increase in Wnt signaling inhibitors (Kang and Robling, 2015). Therefore, participating 
in physical activity or exposure to frequent high-impact exercise could aid the signaling 
pathway in functioning properly. In humans, only a few studies (see below) have been 
conducted to explain the beneficial aspects of physical activity in attenuating sclerostin 
and DKK-1 but there is a lack of information addressing this type of loading. 
This review of the current literature covers the mechanical loading, structure, 
and function of bone cells along with mechanotransduction. Additionally, the signal 
transduction pathway that governs bone metabolism are reviewed. The signal 
transduction pathway enables bone to withstand different forces or adaptation that 
depends on the individual biochemical requirements. Sclerostin and DKK-1 are 
regarded as the most potent regulators of the Wnt signal transduction pathway. Further, 
mechanotransduction is discussed to provide insight on how bone cells can sense and 
transmit signals for initiating the bone formation process, and thus the foundation of the 
signaling pathway as an assessment of bone metabolism. Evidence on mechanical 
loading and bone adaptation in the context of the bone response to physical activity in 
young adult women were reviewed in this section.  
Structural, Functional and Metabolic Properties of Bone  
Bone is a multifunctional connective tissue that protects the vital organs in the 
body and provides mechanical support for the body and recently its role on endocrine 
function has also been studied (Burr et al., 2014). Organic matrix, minerals, and water 
are the major components of the skeleton. The inorganic phase of bone is comprised of 
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hydroxyapatite, which is made from calcium and phosphate that provide structural 
support to the bone (Marcus et al., 2013). The organic phase of bone is comprised of 
type I collagen and a variety of noncollagenous proteins and proteoglycans. It has been 
suggested that bone-specific proteins are important in regulating bone turnover 
precursors (Boskey et al., 1998).   
The macroscopic structure of bone is comprised of cortical or compact and 
cancellous or trabecular bone, which are made of the same cells and matrix but have 
different structural and functional properties. Further, the level of porosity can also 
differentiate cortical and trabecular bone. The cortical bone, which is 80-90% calcified 
and 5-20% porous, is mainly found in the diaphysial shaft of the long bones and 
provides support. The cancellous bone, which is 15-25% calcified and 40-95% porous, 
is mainly found in the metaphysis of the long bones, lumbar spine, and intertrochanteric 
area of the femur and provides a metabolic function (Burr, 2014). Quantitative analyses 
have revealed trabecular thickness and spacing are the major determinants of bone 
stiffness and strength independent of the bone's porosity (Ulrich, 1999). Aging and 
disuse patterns are the major contributors of increasing porosity in trabecular bone.  
Bone homeostasis is maintained by three types of cellular components known as 
osteoblasts, osteocytes, and osteoclasts. The accumulation of micro damage and fatigue 
damage can result in the loss of bone mass if not repaired. The process by which old 
bone is replaced with new bone is known as bone turnover (Burr, 2014). Bone turnover 
is a crucial process, as bone is a dynamic living tissue that can undergo the processes of 
resorption and formation. Bone turnover markers are products released into the blood 
during formation or resorption processes. The preanalytical variables that influence 
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bone turnover marker concentrations include circadian variation, menstrual cycle, 
seasonal variation, fasting versus fed, and physical activity levels (Lombardi et al., 
2012). From a clinical perspective, bone turnover marker analyses provide insight into 
fracture risk and cost-effectiveness of any anti-resorptive therapy. Several methods have 
been used for measurements of bone-turnover markers, such as radioimmunoassay, 
immunoradiometric assay, and enzymatic immunoassay. 
Bone cells are derived from stem cell lineages known as the mesenchymal 
lineage and hematopoietic lineage that regulate homeostasis and immune responses 
(Marcus et al., 2013). The mesenchymal lineage is comprised of bone formation cells, 
type I collagen, and non-collagenous proteins. Osteoblast differentiation is a multistep 
cascade of several transcriptional regulatory factors that enhance proliferation, 
maturation, and termination of osteoblast function. Osteoblasts function to synthesize 
bone matrix, which is located on the bone surface and cuboidal in shape with enlarged 
Golgi apparatus. Osteoblasts express alkaline phosphatase (ALP), osteocalcin, type I 
collagen, and specialized matrix proteins.  
The osteoblastic differentiation process is comprised of proliferation, 
maturation, and termination of the matrix. The expression of alkaline phosphatase 
(ALP), osteocalcin, type I collagen, and other matrix proteins reflect the rate of bone 
formation. ALP and osteocalcin are considered as the early and late markers of 
osteoblast differentiation (Bellido et al., 2014; de Gorter, 2013; ten Dijike, 2013). 
Osteoblast differentiation involves several important signal transduction pathways 
through the activation of transcription factor Runx2. Mice deficient in Runx2 
completely lack osteoblasts and have skeletons without mineralized matrix. BMP, Wnt, 
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and Hedgehog are some of the major signaling pathways that promote osteoblast 
differentiation. Therefore, β-catenin stimulates mesenchymal stem cells to differentiate 
into chondrocyte precursors, which are then converted to immature osteoblasts via 
activation of Runx2, β-catenin, and Dix3/5/6 transcription factors. Further, the 
activation of Osterix leads to the formation of mature osteoblasts. After the completion 
of the formation of mature osteoblasts, some of these cells flatten and cover the bone 
surfaces; these are known as bone lining cells. The influence of PTH activates these 
bone lining cells to produce matrix, and they are also connected with osteocytes through 
gap junctions.  
It has been suggested that bone lining cells function in the bone remodeling 
process by withdrawing from the bone surface and crafting a canopy over the 
osteoblasts and osteoclasts. It has been estimated that 60-80% of the osteoblasts die by 
apoptosis (Bellido et al., 2014; de Gorter, 2013) and remaining osteoblasts flatten to 
cover quiescent bone surface and the remaining of osteoblasts die by apoptosis. 
Therefore, the signaling pathway that occurs during osteoblast differentiation is 
dependent on the types of molecules that ultimately induce bone-promoting cytokines in 
the mesenchymal osteoblast lineage. 
Osteoclasts are the exclusive bone resorption cells of the monocyte-macrophage 
family. Receptor activators of nuclear factor-ƙB ligand (RANKL) and macrophage-
colony stimulating factor are the two cytokines responsible for osteoclastogenesis and 
come from the hematopoietic lineage. During the bone remodeling process, the 
precursors of osteoclasts are retracted to the bone surface and then undergo proliferation 
and differentiation into mature multinucleate cells. The adherence of osteoclasts to the 
17 
bone surface via integrin generates the sealing zone, where secretion of hydrochloric 
acid and acidic proteases occurs. The combined actions of vacuolar H+ and ATPase 
causes acid production, which further couple with the actions of chloride channels and 
chloride-bicarbonate exchangers. The activation of these channels targets acidifying 
vesicles, which fuse with the plasma membrane, causing bone resorption. Lysosomal 
enzymes and metalloproteinases are also secreted during the bone resorption process, 
which further degrades hydroxyapatite and matrix proteins. The sealing zone protects 
the bone surface by providing a tight seal around the ruffle border, which minimizes 
leakage of the resorbed products. Once the resorption process is completed, osteoclasts 
undergo apoptosis and osteoblasts take over the resorbed area, leaving the osteoid tissue 
to undergo calcification (Salo, 1997; Stenbeck, 2002; Teitelbaum, 2003). The 
remodeling process generally requires 3-6 months, with a distinct sequence of 
activation, resorption, and formation. Each sequence involves activation, (8 days), 
resorption (34 days), and formation (120 days or more). The remodeling process occurs 
on the endosteal surface. These processes occur over the entire bone in small sections of 
remodeling packets. 
Osteocytes are mature stellate-shaped cells and make up over 90-95% of all 
bone cells. The bodies of osteocytes are encapsulated in the lacunae and extend their 
cytoplasmic dendritic processes within the mineralized matrix. Quantitative analyses 
have revealed several cytoplasmic projections that emerge from osteocyte cell bodies. 
These projections can communicate with each other through the gap junctions within 
the canaliculi. These gap junctions are formed by the proteins known as connexins. 
18 
Accumulating evidence suggests that connexins can function through the hemichannels, 
which are important precursors for anti-apoptotic activity (Bonewald, 2011).  
Osteocytes in contact with the surface of the osteoblasts respond to tmechanical 
loading via a lacuna-canalicular network. It has been reported that cyclic mechanical 
loading of osteocytes is responsible for the flow of bone fluid by extravascular pressure 
(Klein-Nulen, 2013).  Besides mechanosensory function, osteocytes regulate phosphate 
homeostasis, reflecting their role in endocrine function and recently it has been reported 
that the use of glucocorticoids leads to the apoptosis of osteocytes (Bonewald, 2011). 
The apoptosis of osteocytes reduces to sense microdamage or repair signals (Bonewald, 
2011).  
Mechanotransduction 
The human skeleton is composed of amazing engineering of three types of bone 
cells: osteoblasts, osteocytes and osteoclasts. These bone cells are regulated via several 
cellular processes and in the presence of mechanical loading these cellular signals are 
converted to biological signals, which influence the bone remodeling processes. 
Osteocytes play an important role in mechanotransduction, an important mechanism to 
control bone homeostasis (Klein-Nulen, 2013; Spyropoulou et al., 2015) and any 
alterations in this process can increase the risk of bone diseases (Cox, 2011).  
The exact mechanism of sensing the mechanical loads by osteocytes is still not 
completely understood. However, accruing evidence supports that mechanical loading 
causes flow of interstitial fluid within the osteocyte and its dendritic processes stimulate 
the signaling molecules that regulate the process of bone formation and resorption 
(Huiskes et al., 2000). The various mechanical signals such as tissue strain, hydrostatic 
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pressure, and streaming potentials can activate osteocytes. Further, in vitro and in vivo 
studies have suggested that in the absence of mechanical loading osteocytes produce 
factors that stimulate the osteoclasts and that the presence of mechanical loading 
stimulates upregulation of Wnt/β-catenin target genes and down regulation of sclerostin 
(Santos et al., 2009; Galea, 2011). Bell et al. (2008) has proposed that the primary 
cilium of osteocytes is able to sense the hydrostatic pressure generated from the 
mechanical loading, but no in vitro research has been done to test this hypothesis. 
Therefore, the exact mechanisms by which the cellular components or the sense 
complexes that are situated in the osteocytes contribute to mechanotransduction remain 
unclear. Connexins are considered to be important in communicating among osteocytes, 
especially connexin 43; a lack of connexin 43 increased osteocyte apoptosis with 
increased osteoclastogenesis (Zhang et al., 2011). Therefore, there is still a lack of 
evidence regarding the exact structural features that activate osteocytes to function as 
mechanotransducers.  
The knowledge of what causes osteocytes to respond to mechanical stimulation 
suggests that various mechanical signals are responsible for evoking this process. The 
production of nitic oxide, prostaglandins, Wnt signaling, bone morphogenetic proteins, 
and integrin signaling can bridge the gap between mechanical loading and biological 
responses (Gardinier et al., 2010). The discovery of the Wnt signaling pathway has 
added to the repertoire of molecules mediating mechanotransduction in bone. Wnt 
signaling is an important modulator of the bone formation process and can be activated 
by β-catenin pathways via kinases or GTPases (Kamel, 2010). It has been reported that 
mechanical loading influences MC3T3-E1, an osteoblast precursor derived from mouse 
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calvaria, to increase Wnt gene expression. This finding explains how pulsating fluid-
flow upregulates mRNA expression of the β-catenin pathway in the signaling cascade 
and indicates the importance of Wnt signaling in osteocyte biology (Cui et al., 2011).  
The expression of sclerostin is found to be higher in mature osteocytes, where it 
is transported to the bone surface via canaliculi and inhibits bone formation. Studies in 
animal models have suggested that sclerostin can bind with Wnt co-receptor Lrp5 and 
inhibit bone formation, where unloading increases SOST expression in the tibia 
(Robling, 2006). The accumulating evidence suggests that signaling molecules play an 
important role in orchestrating the recruitment of osteoblasts and osteoclasts, which 
































Wnt proteins are important secreted proteins that regulate development, 
differentiation, the function of various cells and tissues in living organisms. The 
signaling of Wnt proteins occurs through several pathways, but the Wnt/β-catenin, or 
canonical, pathway is the most important for understanding bone biology (Westendorf, 
2004). The binding of Wnt/β-catenin to the 7-transmembrane domain Frizzled receptor 
and low-density lipoprotein receptor-related protein 5 and 6 (LRP5/6) coreceptors 
causes its activation (Moon, 2004). The activation leads to the stimulation of axin and 
frat proteins, which inhibit the activity of glycogen synthase kinase (GSK3) and 
hypophosphorylated β-catenin. The formation of stabilized β-catenin then accumulates 
and translocates in the nucleus, which enhances the transcriptional coactivator to 
interact with T cell factor and lymphoid enhancer binding factor (TCF/LEF) for Wnt 
gene transcription (Hay, 2005; and Logan, 2004) as shown in Figure 2.   
Wnt interacts with its receptors through canonical and non-canonical signaling. 
Canonical and non-canonical signaling are important for skeletal homeostasis; however, 
only canonical signaling function with the activation β-catenin Wnt signaling is a tightly 
regulated pathway and is inhibited by Wnt inhibitory factors such as sclerostin and 
DKK-1. LRP5/6 coreceptor activity is also inhibited by these factors. Interaction with 
this antagonist regulator will cause degradation of β-catenin before it translocates into 
the nucleus and thus suppresses gene transcription (Mao et al., 2002). 
 Both LRP5 and LRP6 are essential for the development of normal postnatal 
bone and it has been reported that LRP5 activates bone formation whereas LRP6 
stimulates both formation and resorption (Riddle et al., 2013). LRP6 knockout mice 
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showed a change in osteoclast activity with a significant reduction in osteoblast number 
compared to wild-type mice (Li et al., 2013). The fluorescence resonance energy 
transfer technique was used to show that LRP6 plays an important role in PTH signaling 
but no evidence in activating Wnt pathway through mechanical loading compared to the 
crucial role of LRP5 in mechanotransduction (Wan et al., 2008; and Sawakami et al., 
2006). This evidence is important to determine the role of LRP5/6 for Wnt and hormone 
signaling in regulating bone homeostasis.  
 Additionally, β-catenin is responsible for the differentiation of osteoblasts, 
stimulating preosteoblast replication and inhibiting osteoblast apoptosis through a 
different mechanism in postnatal bone growth (Kato et al., 2002; Reya et al., 2005). 
Mice deficient in β-catenin expression exhibit progression of bone loss, demonstrating 
the importance of β-catenin in bone biology (Kramer et al., 2010). Therefore, alterations 
in the expression of β-catenin directly influence the Wnt pathway. The mechanisms of 
how the Wnt signaling pathway regulates bone mass suggest the generation of 
osteoblasts from the differentiation of mesenchymal stem cells in the osteoblast lineage 
together with the suppression of the chondrogenic and adipogenic lineages. Wnt 
signaling reduces apoptosis of that mature osteoblast and increases the expansion of 
osteoprogenitor cells via the activation of β-catenin, suggesting the important role or 
Wnt signaling in bone formation (Almeida et al., 2005; Modder et al., 2011). Deletion 
of Wnt/β-catenin signaling pathway increases osteoclast number and reduces the bone 
forming cells (Wei et al., 2011).  
Growing evidence suggests that age-related decline in bone mass often results in 
osteoporosis and the attenuation of Wnt/β-catenin is associated with the loss of bone 
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mass. Also, aging is associated with an increase in oxidative stress that causes β-catenin 
in the osteoblast progenitors to follow forkhead family of transcription factors (FoxOs) 
pathway rather than Wnt. This FoxO pathway leads to attenuation of β-catenin activity, 
which further decreases the formation of osteoblasts. Therefore, this diversion usually 
contributes to the age-related changes in the bone mass and increased osteoporosis (Van 
der Host, 2007; Salih, 2008; Manolagas, 2007; Alemeida, 2007; Lopez-Otin, 2013). 
Sclerostin 
The Wnt/β-catenin signaling pathway is fine-tuned by secreted glycoproteins 
that act antagonistically with the signaling pathway. Sclerostin and DKK-1 are 
recognized as the most potent negative regulators of the Wnt/β-catenin signaling 
pathway. Sclerostin is the product of the SOST gene and is the member of CCN protein 
family that interacts with LRP5/6 and inhibits the Wnt pathway. Defects in sclerostin 
have been associated with increased bone mass; in humans, this is known as Van 
Buchem disease. However, the overexpression of SOST alleles is associated with loss of 
bone mass (Agholme et al., 2011).  Knockout of the SOST gene in mice has also 
revealed increased trabecular and periosteal bone mass (Li et al., 2009). Recent findings 
suggest that sclerostin is highly expressed in osteocytes and its expression is decreased 
in the presence of mechanical loading (Robling et al., 2006).  
Current therapies for the treatment of bone loss are exclusively based on the 
antiresorptive approach; therefore the development of an antisclerostin neutralizing 
antibody could provide novel treatment for osteoporosis. During the process of bone 
remodeling, the secretion of sclerostin by osteocytes stimulates the negative feedback 
mechanism and prevents BMU overfilling. The modeling process is carried out by 
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preventing the activation of osteoblasts so that bone lining cells are devoid of 
osteoblasts. The identification of gain-of-function and loss-of-function mutations 
suggests that sclerostin bind with LRP5/6 and inhibit the canonical pathway. 
Recombinant human PTH is considered to be a possible regulator of SOST expression; 
therefore, it is used in the treatment of osteoporosis.  
The exact mechanism is still not clearly understood, but it has been reported that 
the increased sclerostin expression after the application of glucocorticoids can be fine-
tuned by PTH and mechanical loading (Yao et al., 2008). Gaudio et al. (2010) compared 
sclerostin levels in postmenopausal women who cannot mobilize due to stroke to levels 
in age-matched control subjects. This study found that serum sclerostin was higher in 
the immobilized subjects compared to the controls, with no change in DKK-1 levels 
suggesting a potent role of the SOST in addressing strain-induced bone changes. 
DKK-1     
DKK genes are comprised of conserved members (1-4) that encode secreted 
glycoproteins with a cysteine-rich domain. The conserved member DKK-3 is not able to 
inhibit the Wnt signaling pathway. However, DKK (1, 2 and 4) can interact with 
LRP5/6 in the Wnt signaling pathway. The cysteine domain-2 of DKK-1 gene shows 
high-affinity binding with LRP5/6 which is enough to inhibit the Wnt signaling 
pathway (Mao et al., 2002). Reducing the DKK-1 expression in mice resulted in the 
high bone mass and increasing its expression resulted in osteopenia. These results lead 
one to surmise that DKK-1 plays an important role in bone formation and can be a 
target for pharmacological intervention in the treatment of bone diseases (Morvan et al., 
2006; Li et al., 2006; Roodman, 2006).  
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Bone mass homeostasis occurs from the mesenchymal stem cell line which 
undergoes the signaling pathway that leads to the formation of osteoblasts. It has been 
reported that DKK-1 inhibits osteoblastogenesis by disrupting the osteoblast 
differentiation pathway, which prevents endochondral osteoblasts formation (Chen et 
al., 2007). It has been well documented that osteoprotegerin and RANKL are 
responsible for the bone formation and resorption and the ratio of osteoprotegerin and 
RANKL determines the net effects of resorption (Diarra et al., 2007). Studies in animal 
models suggest that DKK-1 exerts a negative effect on osteoprotegerin expression that 
favors the increased resorption activity by shifting the osteoprotegerin and RANKL 
ratio (Diarra et al., 2007). Also, mechanical loading decreases the expression of 
sclerostin and DKK-1, supporting the importance of mechanical loading in the 
pathogenesis of disuse bone loss (Gaudio et al., 2010).  
Mechanical Loading 
Mechanical loading and bone adaptation is a complex process and various 
models have been utilized to gain insight into this adaptive process. Also, mechanical 
loading is an integral part of the development and growth of a weight bearing skeleton 
(Turner et al., 2009). As proposed in the Utah Paradigm of Skeletal Physiology, bone 
formation and resorption occur when the mechanical strains are higher and lower than 
the strain threshold (Frost, 1999). When modeling is turned “ON”, a strain threshold is 
surpassed and when it is turned “OFF, a strain remain below its threshold. Similarly, the 
term "remodeling" is used to signify strains below the modeling threshold, when 
modeling is OFF. Bone remodeling involves several threshold ranges such as 
“conservation mode” and “disuse mode.” When bone formation and resorption are 
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equivalent, strains just below the threshold are the “conservation mode.” When bone 
resorption exceeds formation, leading to loss of bone mass, and strains are below the 
conservation mode, the bone is considered to be in “disuse mode”. Prolonged reduction 
of strain in disuse ensues the condition known as “disuse-pattern-osteopenia,” which 
can be acute or chronic and can be characterized by normal bone but larger marrow 
cavities. Further, Frost (1999) explained that the modeling and remodeling processes 
are driven by drifts and basic multicellular units (BMUs).  
Muscle also plays an important role in postnatal bone strength and mass. The 
voluntary loads and strains can be influenced by muscle contraction. As a person ages, 
the pattern of muscle strength increases and then plateaus, and after 30-40 years, a 
gradual loss of muscle strength takes place that is similar to loss of bone mass. 
Compared to muscle strength, the bone formation and resorption process is slower and 
takes time for adapting to the usual strain that is placed on it. Thus, mechanical loading 
provides a positive influence on the skeletal strength that can withstand the load and 
prevent a fracture that could be due to age-related bone loss, disuse, or microgravity 
environment (Price et al., 2011). Further, that bone loss can be reduced by increased 
physical activity is a local phenomenon for the adaptive response and can be locally 
controlled (Sugiyama et al., 2010).  
However, the mechanostat theory described above is not able to explain how 
bone cells stimulate the processes of bone formation and resorption. Animal model 
study has explained the extrinsic mechanisms for mechanical loading where bone 
adaptation is dependent on the frequency and the magnitude of the strain the bone 
experiences (Meakin et al., 2014). These mechanisms indicate that static load of zero 
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frequency would not influence bone adaptation process. Further, based on Turner’s 
rules, adaptation can be acquired either through increased strain magnitude and 
decreased frequency or decreased strain magnitude and increased frequency. Similarly, 
the concept of diminishing returns after prolonged exercise in rats suggests that the 
anabolic response showed no benefit on bone after increasing the loading cycle or 
duration (Umemura et al., 1997). Also, adding a 14-second rest period between the 
loading cycles can improve bone formation and suggests that rest is necessary for the 
osteogenic stimulus (Robling et al., 2001). 
In addition, various types of exercise such as treadmill running, jumping, and 
swimming in animal models have helped researchers to understand that the mechanostat 
theory (Yeh et al., 1993; Bourrin et al., 1992; Ju et al., 2012), which can be applied in 
human studies. The positive relationship between bone mass and exercise has 
encouraged researchers to recommend that individuals engage in a physical activity so 
that the risk of osteoporotic fracture can be reduced. Given that prolonged exercise 
duration can influence the bone cells to ignore mechanical loading and the development 
of an osteogenic index (OI), explain the effectiveness of exercise protocols on bone 
mass (Turner and Robling, 2003). The utilization of OI by several studies reported that 
OI activities decline with age. As a predictor of bone health, the OI uses ground 
reaction forces, duration, and frequency of participating in a given physical activity 
(Nilsson et al., 2009). 
Bone Responses to Physical Activity in Premenopausal Women  
 Frost’s Utah paradigm of skeletal physiology has contributed insight that there is 
a threshold above which bone must be stressed in order to be adapted. With the various 
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animal and human studies it has now been clearly established that physical activity has 
provided a positive influence on skeletal mass.  
  With this perspective from Turner’s three rules for bone remodeling, loads must 
be dynamic, non-routine, and short duration; mechanical strains should have progression 
of overload because bone cells will adapt and will not respond to the customary loading. 
The time frame of a complete bone loading requires 3-6 months and the training studies 
are required to detect the changes in the bone parameters via invasive and non-invasive 
techniques. Therefore, many studies have quantified the influence of physical activity in 
bone health through longitudinal studies, cross-sectional studies and through meta-
analyses of different populations. Age also plays an important to a role in determining 
the effect of physical activity on skeletal health. The age at which an individual 
participates in high impact exercise and if the activity level is continually maintained 
throughout the life are some of the major determinants of the influence of physical 
activity on bone health. One study examined the association of physical activity and 
bone mass in healthy women and found that physically active young women with high 
calcium intake had higher bone mass in distal tibia trabecular bone compared to 
physically active postmenopausal women. The results suggest that mechanical loading in 
young age is important for long-term conservation of mechanical loading (Uusi-Rasi et 
al., 1998).  
In a 28 year follow-up study, the habitual childhood and adolescent physical 
activity or inactivity on tibial pQCT bone at the age of 3-18 years was assessed. Further, 
at the age of 31-46 years, assessment of cortical and trabecular bone density was 
performed. The results suggest that childhood physical activity was associated with 
31 
increased cortical area of the tibia, BMC, and SSI in premenopausal women. This led 
the researchers to conclude that that frequent habitual physical activity in adolescence 
provides a positive influence on tibial bone size and geometry as individuals age 
(Tolonen et al., 2015). 
Sherk et al. (2010) conducted a study to compare bone mineral density and bone 
quality in adult rock climbers, resistance-trained men, and control subjects. The results 
showed that resistance-trained young men had a significantly higher lumbar spine and 
femoral neck BMD compared to rock climbers and control men. However, no 
significant differences were observed for the cortical bone variables. The results suggest 
that bone adaptations among climbers could have been restricted to some specific sites 
such as the fingers, which could experience loads above modeling threshold. 
One cross-sectional study reported the effect of past sports activity on bone 
density parameters in both men and women (Kato et al., 2014). Both men and women of 
20-23 years participated in the study, where MRI and DXA were used for the body 
composition and bone density assessments, respectively. Women participating in sports 
activity in elementary school had significantly higher BMC, total proximal femur, and 
muscle-cross-sectional area compared to women in the no sports group. Also, OI was 
found to be correlated with MRI measures of bone geometry, whereas DXA variables 
were considered as effective indicators of past activity both in men and women. The 
results of this study suggest that participating in high impact exercises before and early 
puberty showed enhanced femoral mid-diaphyseal bone geometry (Kato et al., 2014).  
  In a cross-sectional study, the effects of physical activity on cortical bone in 
jumpers, swimmers, and untrained control groups was studied using pQCT. It has been 
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well established that loading and frequency play important roles in bone adaptation that 
can then further influence the geometric properties of bone. The results on  tibia 
analyses showed that polar moment of inertia and SSI, area and thickness were 
significantly higher in jumpers compared to swimmers and the control group. Similarly, 
female jumpers had significantly higher cortical BMC, SSI, thickness, and area but 
lower vBMD, suggesting that jumpers could have strong bone to overcome of the 
compressive and bending strains. Similarly, in swimmers, the enlarged endocortical 
area could be due to the early training and influence from the endocrine system. 
Therefore, long-term participation in physical activity by athletes is associated with 
increased cortical geometric adaptations rather than vBMD improvements (Liu et al., 
2003). 
Jumping mechanography is an important tool in the assessment of muscle 
function and peak strains, and the peak power can be calculated as the product of force 
and velocity via countermovement jumps. It has been now well documented that peak 
power represents the activity of hip, thigh and calf muscles, whereas peak force reflects 
Achilles tendon elasticity (Anliker et al., 2011; Veilleux, 2010). Heinonen et al. (2001) 
conducted a cross-sectional study to investigate the influence of extreme impact loading 
on bone parameters with the DXA and pQCT in 8 triple jumpers and controls. The 
results showed that femoral neck and lumbar spine were 31% higher in jumpers 
compared to controls. Similarly, distal femur and BSI measurements were 4-6 and 19-
31% higher among jumpers compared to the control group. In jumpers, the loading 
effect was observed higher in the cortices after an increase in the trabecular densities.  
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Another cross-sectional study compared bone mass and geometry among long 
and middle distance runners, race-walkers, sprinters and sedentary control participants 
(Wilks et al., 2009). Female sprinters and middle distance runners had 15% and 12% 
larger cross-sectional polar movement of resistance and higher trabecular vBMD than 
control. Surprisingly, cortical vBMD was highest in the controls, while cortical BMC, 
area, and strength were higher in the sprinters. The results suggest that running speed is 
positively associated with geometric tibia measures whereas cortical vBMD is 
negatively associated with loading frequency (Wilks et al., 2009). Further, a meta-
analysis study on exercise and BMD in premenopausal women (7 studies, n=466, g= 
0.342 for femoral neck; 6 studies, n=402, g=0.201 for lumbar spine) reported that 
participating in exercise for more than 24 weeks significantly increased femoral neck 
and lumbar spine BMD. In this study, standardized effect sizes were calculated for each 
result and pooled using random-effect models (Kelley et al., 2013). 
A study of short-term jump activity on bone metabolism by Kishimoto et al. 
(2012) reported that two weeks of jump activity consisting of 10 jumps/day 
significantly decreased bone resorption markers in 26 non-athlete females of 19-24 
years of age. Further, this study also revealed a significant decrease in the early marker 
of bone formation, bone alkaline phosphatase, and no change in the late marker 
osteocalcin. The results suggest that short training protocols can attenuate the bone 
turnover markers and controling the time intervals, diet, and use of contraceptives can 
influence the bone formation markers. 
 Similarly, a study by Baxter-Jones et al. (2008) reported the relationship 
between physical activity and bone mass from young to adult phase both in men and 
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women. Subjects were categorized into active, average and inactive groups and the 
results showed that active adolescent females had 9 % and 10% more adjusted BMC, 
total hip and femoral neck compared to the inactive group. The researchers surmised 
that participating in physical activity conserved the skeletal benefits throughout the 
adult phase.  
In the assessment of jumping mechanography on hip BMD, Tucker et al. (2015) 
used a longitudinal study to determine the effect of two jumping programs in 
premenopausal women. Sixty premenopausal women ages 25-50 years participated in 
the study and were categorized into three groups of jump 10, jump 20, and control. 
DXA was used for the hip BMD assessment during baseline, at 8 weeks, and at 16 
weeks. Subjects were instructed to jump on a force plate at 30 secs intervals for 10 
jumps for jump 10 group and 20 jumps for jump 20 group. Control subjects were 
instructed to perform stretch for a total of 10 minutes for 6 days. The unadjusted percent 
change in hip aBMD at 8 weeks was significantly greater in the jump 20 group 
compared to the control and there was only a marginal increase in the jump 10 group. 
Similarly, at 16 weeks after adjusting for confounding variables, hip aBMD was 
significantly higher (p=0.009). These results suggest that high impact exercise, such as 
jumping 20-30 times daily, can improve the skeletal health and prevent fracture risk in 
the future. 
In a randomized, controlled trial study by Bailey and Brooke-Wavell (2010) 
categorized premenopausal women of 18 -45 years into exercise and control groups. 
The exercise group was further categorized into 0, 2, 4 or 7 days/week for 6 months 
with sets of 10 hops on one limb followed by 15 seconds of walking. This study aimed 
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to investigate the effectiveness of high-impact exercise on BMD. DXA was used for the 
body composition and bone density assessment. The results showed significantly 
increased peak ground reaction forces and 2% in femoral neck BMD in the exercise 
group compared to the control group, suggesting the positive influence of high-impact 
exercise on reducing hip fragility.  
Liang et al. (2011) conducted a randomized control trial to evaluate the effect of 
high impact exercise in premenopausal women between 20-35 years. In this study, 
subjects were randomly assigned to high impact aerobic exercise, moderate intensity 
strength training, or a control group. Whole body and heel and wrist aBMD were 
measured using DXA. After a 12-month intervention, there was an increase in heel 
aBMD (4.4%) and leg press strength compared to the baseline, but no significant 
increase in aBMD was observed. Most of the untrained women were at their peak 
aBMD level and small sample size could have attributed the lack of statistically 
significant findings. 
 Similarly, Warren et al. (2008) conducted a longitudinal study in premenopausal 
women of ages ranging from 25-44 years old. This study included 148 sedentary 
premenopausal women categorized into strength treatment and control group. Subjects' 
bone density parameters were measured at baseline, 12 months and 24 months. DXA 
was used for the assessment of body composition, bone mineral content, aBMD, and 
bone area of the proximal femur and lumbar spine. Leg press and bench press were used 
for the muscle strength assessment, with these measurements separated by two weeks. 
Physical activity assessment was performed by accelerometer where subjects were 
instructed to wear the device for 4 days. There was a significant difference between the 
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two groups for femoral neck BMC, with 1.5% decrease in the control group suggesting 
the importance of mechanical loading in bone health.  
Sclerostin and DKK-1 Responses to Physical Activity 
  Signaling pathways allow a bone to adapt depending on its biomechanical 
requirements. In animal models, it has been shown that mechanical loading decreases 
sclerostin production and unloading increases SOST production. Gaudio et al. (2010) 
conducted a cross-sectional study in 40 elderly women who were immobilized for 6 
months after stroke and 40 control subjects to determine the effect of unloading on bone. 
Bone turnover markers, sclerostin, and DKK-1 were measured from serum samples. The 
results revealed significantly higher bone resorption markers and sclerostin levels in 
immobilized women compared to controls. However, no significant differences were 
observed for DKK-1 between the groups. The results suggest that disuse or lack of 
mechanical loading could accelerate the increase in those markers, which could result in 
the disuse pattern of osteoporosis. 
  In a cross-sectional study, Mirza et al. (2010) compared pre- and 
postmenopausal women and correlated sclerostin with free estrogen, bone markers, and 
parathyroid hormone levels. In this study, the average age of premenopausal and post-
menopausal women was 26.8 and 56.8 years, respectively. The results showed that 
serum sclerostin levels were significantly higher in postmenopausal women compared to 
premenopausal women. Also, negative correlations were observed between levels of 
sclerostin and both free estrogen and parathyroid hormone in postmenopausal women 
suggesting that estrogen deficiency causes secretion of more sclerostin in the circulation 
and might regulate bone by acting as an endocrine hormone. Further, this study included 
37 
contraceptive users with variety of sex hormones, which make difficulty in assessing the 
total estrogen in premenopausal women. A cross-sectional study by Garnero et al. (2013) 
that reported parathyroid hormone levels were negatively associated with sclerostin 
levels, but different in that no significant association with estradiol levels was observed. 
  A cross-sectional study by Amrein et al. (2012) investigated sclerostin's 
association with age, gender, bone variables, and levels of physical activity. This study 
included 161 healthy men and 34 premenopausal women who had their sclerostin, BMD, 
biochemical parameters and physical activity levels evaluated. The results showed that 
men had significantly higher unadjusted sclerostin levels compared to premenopausal 
women and all the premenopausal women were younger than male subjects. No 
significant correlation was observed between sclerostin and the measured biochemical 
parameters. However, adjusting for confounding factors such as skeletal size (men had 
21% higher skeletal mass), age and physical activity levels, sclerostin levels did not 
differ significantly between the genders.. Overall, in healthy adults, most physically 
active individuals had significantly lower sclerostin levels than less active individuals. 
However, this conclusion cannot be applied to premenopausal women, as the sample size 
was comparatively lower than for adult men and the use oral contraceptive was not 
reported.  
  Ardawi et al. (2011) studied the determinants of serum sclerostin in healthy pre- 
and postmenopausal women between the ages 20-79 years old. This study also aimed to 
establish the normative reference values for sclerostin, age-related changes and effect of 
menopause. A total of 1,803 women participated in the study and the premenopausal age 
range was 20-45 years old. The results showed that postmenopausal women had 
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significantly higher levels of osteocalcin and some bone resorption markers compared to 
premenopausal women. Also, postmenopausal women showed higher sclerostin levels. 
The regression analyses showed that sclerostin increased linearly with age, with a steep 
increase until age 35, remained stable between 35-45 years and increased sharply again 
after that 45, suggesting the importance of sclerostin with aging.However, from the 
exercise perspective, this study lacks an explanation about physical activity levels in 
both pre- and postmenopausal women to address the relationship between mechanical 
loading and sclerostin levels. 
  Modder et al. (2010) conducted a cross-sectional study to determine the 
relationship of age, gender and bone mass with sclerostin levels in men and women. This 
study included 318 men and 362 women, both pre- and postmenopausal. The results of 
this population-based study showed that men have significantly higher sclerostin levels 
than women (33.3 ± 10. pmol/L versus 23.7 ± 0.6 pmol/L). Sclerostin levels were 
significantly higher with aging in both men and women. The authors noted that the 
higher sclerostin levels in men could be due to their greater skeletal mass that produces 
more circulating sclerostin. The specific dose response between sclerostin and inhibition 
of bone formation is still unclear, which necessitate to determine the dose-response 
relationship between bone formation and bone markers. 
  Ardawi et al. (2012) conducted a cross-sectional study with a subgroup followed 
up longitudinally to determine the physical activity response of sclerostin levels in 
premenopausal women. In this study, 58 women were followed longitudinally during an 
8-week course of physical activity training (4d/wk) and compared with 62 control 
subjects. The exercise protocol included 120-min sessions for 4 d/wk, with 20 min 
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walking at increased speed and an endurance physical activity of 25 min running, 
walking on the treadmill for 20 min, cycling for 10 min, and step-ups for 10 min. These 
exercises were followed by flexion, extension and mobility exercises for upper and lower 
body for 35 min. After the completion of 8 weeks training, women participating in the 
physical activity training for 4d/wk had significantly lower sclerostin levels compared to 
the sedentary individuals. Following the 8 weeks intervention, sclerostin levels were 
significantly lower by 33.9% but significantly higher bone formation markers in the 
physically active training group, suggesting the importance of mechanical loading in 
skeleton biology. 
   Butler et al. (2011) conducted a study correlating the expression of DKK-1 with 
BMD. In this cross-sectional experimental cohort study, 18 patients with low BMD and 
18 with normal BMD (23 female and 13 male) participated. DXA was used for the BMD 
analysis of lumbar and femoral sites. DKK-1 levels were significantly higher in the 
osteoporosis group compared to control (p=0.001). Further, serum DKK-1 levels were 
inversely associated with femur t-score, lumbar z-score, and femur z-score (p<0.05). The 
results suggest that expression of DKK-1 is a pivotal aspect in the assessment of 
osteoporosis. However, in this study, no significant correlation between aging and DKK-
1 was observed. Also, this paper did not report the physical activity levels of the 
subjects. 
  A cross-sectional study on ultramarathon runners has shown a significant 
decrease in DKK-1 levels after the marathon but no changes in sclerostin levels 
(Kerschan-Schindi et al., 2015). In this study, 19 participants had venous blood samples 
drawn before, immediately after and 3 days after the start of the race. The researchers 
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also found bone formation marker significantly decreased after the race and showed a 
trend of increase thereafter. The bone resorption marker (CTX) was significantly 
increased after the race and showed a trend of decreasing thereafter. The results suggest 
that exercise is associated with low-level inhibition of Wnt signaling inhibitors, thereby 
increasing the differentiation of bone-forming cells. Therefore, short-term participation 
in an ultradistance race influences the uncoupling of bone turnover but endurance 
exercise also seems to initiate a long-term positive influence on skeletal mass.  
  To study the disuse-induced bone loss, Frings-Meuthen (2013) conducted a 
cross-sectional study to determine sclerostin and DKK-1 levels in the bed-rest condition 
in young males. One group participated in 14 days head down tilt bed rest and the other 
group participated in 21 days bed rest, respectively. In both groups, sclerostin levels 
increased during the bed rest and declined at the end of 14 and 21 days. In study 1, 
DKK-1 decreased from baseline level until the recovery period, whereas the 21-day 
study showed increased DKK-1 levels and decreased 3 days after the end of bed rest. 
The 14-day bed rest group did short walks that could have caused the decrease in the 
DKK-1 levels. The results suggest that DKK-1 reacted faster to unloading compared to 
sclerostin as DKK-1 could have higher affinity to LRP5/6, which trigger osteocytes to 
increase DKK-1 levels. However, small sample size could have affected the results, but 
the concluding point was that disuse can alter the Wnt signaling pathway by increasing 
sclerostin and DKK-1. 
  One randomized study reported the levels of serum sclerostin in 107 female 
sedentary obese older subjects in response to the exercise training. Subjects were 
categorized into control, diet, exercise, and diet-exercise group. The exercise groups 
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were instructed to perform aerobic, resistance training, and balance exercises for 1 year. 
Bone density and sclerostin measurements were collected at baseline, 6 months and 12 
months. No significant changes in sclerostin levels were observed from baseline to 12 
months except for the diet group, where a significant increase was observed at 12 months 
(p<0.05). Further, hip geometry analysis showed deteriorating results in the cortical 
thickness, area and femoral shaft for the diet group. However, no significant changes 
were observed for the exercise-diet group. The results suggest that exercise training 
improved BMD and bone geometry and, when added to the diet, it may inhibit the 
weight loss-induced increase in sclerostin. This could further attenuate bone loss and 
preserve bone geometry (Armamento-Villareal et al., 2012). 
  Mosti et al. (2014) conducted a randomized controlled trial in the assessment of 
BMD with maximal strength training. This study included 30 healthy women of 18-27 
years who were categorized into a training group and control group. The training group 
performed 12 weeks of squat maximal strength training with 85-90% 1RM focusing on 
progressive loading with high acceleration in concentric phase. Both groups had baseline 
and post-test measurement of physical capacity parameters, anthropometric parameters, 
BMD, and serum markers. The dynamic rate of force development and peak force and 
1RM were significantly higher in the training group compared to the control group.   
Similarly, BMD and BMC at the lumbar spine increased by 2.2% and 3.4% respectively, 
in the training group (p<0.05). No significant changes occurred in the levels of sclerostin 
and bone resorption markers. This paper indicated that low sample size and duration of 
the training could have altered the results. These results were consistent with the study 
42 
conducted by Kovarova et al. (2015), where no significant changes were observed for 
sclerostin levels following the resistance exercise. 
Summary 
  Accumulating evidence suggests that mechanical loading is the crucial 
modulator for bone metabolism. Animal models have shown that disuse or unloading 
patterns can cause reduced bone formation, which can be connected with human studies 
exploring issues such as sedentary behavior, bed rest, and paralytic condition. 
Conversely, participating in high-impact loading is associated with active bone 
formation. The exact involvement of physical and biological mechanisms in bone 
adaptation is still not clear, but some biological key players to control 
mechanotransduction have been identified. These players include the flow of interstitial 
fluid within the osteocytes, which stimulates the signaling molecules that modulate the 
bone formation and resorption process. The activation of osteocytes occurs by various 
mechanical signals such as tissue strain, pressure, and other streaming potentials. 
Substantial evidence suggests that signaling pathways play important roles in regulating 
the process of bone metabolism. The Wnt signaling pathway transduces the mechanical 
signals and regulates bone metabolism. However, the unloading pattern increases the 
release of sclerostin and DKK-1 at the endosteal surface of the long bones. Therefore, 
better insight into the complex association between physical activity and signaling 
markers such as sclerostin and DKK-1 will provide an early approach for identifying 
fracture risk in osteoporosis.  
 The increase in BMD during early puberty is followed by a slower increase in 
BMD and consolidates the mineral during the early thirties until the peak bone mass is 
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achieved (Clarke and Khosla, 2010). Therefore, maintenance of bone mass during the 
premenopausal phase is important as age progresses. To conserve bone mass, it is 
necessary to expose the skeleton to mechanical loading or exercise. Based on the 
literature, it has been well established that various high-impact exercises can decrease 
those Wnt signaling inhibitors, facilitating the bone forming cells. Also, 
epidemiological evidence suggests that physical activity or exposure to high impact 
exercise can reduce fracture risk and improve muscle force and coordination. 
Therefore, findings from the literature necessitate framing the type and duration of 
physical activity that decrease the production of sclerostin and DKK-1, which will then 
prevent bone formation cells from undergoing apoptosis.  
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Chapter 3: Methodology 
The primary purposes of this study were to: (1) compare serum concentrations 
of sclerostin and DKK-1 in young (20-30 years) and middle-aged (35-45 years) 
premenopausal women; (2) evaluate the differences in serum sclerostin and DKK-1 
concentrations based on the physical activity status (low, moderate, and HEPA-active).  
The secondary purposes of this study were to: (1) evaluate relationships of sclerostin 
and DKK-1 with aBMD and volumetric bone mineral density (vBMD) in young and 
middle-aged premenopausal women; (2) evaluate relationships of sclerostin and DKK-1 
with leg strength; and (3) evaluate relationships of sclerostin and DKK-1 with jump 
power. Dependent variables included the serum levels of sclerostin and DKK-1; aBMD 
and BMC of the total body, lumbar spine, and dual femur; vBMD of the trabecular and 
cortical bone at 4%, 38%, and 66% of the tibia. This chapter describes the methods used 
for this study, including sample sizes, data collection procedures, and data management 
and analyses steps. 
Participants 
Participants for this study were premenopausal women between ages 20-30 
years (n=25) and 35-45 years (n=25), and of diverse ethnicity. Participants were 
recruited from the Norman and Oklahoma City Metropolitan area via mass email, 
flyers, classroom recruitment, message recruitment, word-of-mouth, and advertisement. 
Prior to the first visit to the Bone Density Research Laboratory for testing, participants 
were screened via a screening checklist. All the protocols were approved by the 
University of Oklahoma Health Sciences Center Institutional Review Board before the 
start of this study (IRB No. 6945) (Appendix A).  
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Participants were screened based on the screening checklist questionnaire 
through email, phone or in person. Participants were excluded from the study if they 
met any of the exclusion criteria based on their responses to the screening questionnaire 
(Appendix C). Eligible participants were scheduled for the first visit to the Bone 
Density Research Laboratory. During the first visit, each participant completed the 
written informed consent, HIPAA form, health screening questionnaire, calcium intake 
questionnaire, menstrual history questionnaire, BPAQ, and IPAQ (Appendix B).  
The available data on Wnt signaling inhibitors in humans, particularly in young 
and middle-aged premenopausal women, are sparse. The sclerostin results from a cross-
sectional study in pre- and postmenopausal women published by Modder et al. (2011) 
were used to perform a power analysis using G*Power 3.1 (Faul et al., 2007). The effect 
size (d) for sclerostin differences between pre- and postmenopausal women was 
determined to be 1.18, a large effect size (Cohen, 1992). This effect size was used to 
estimate the required sample size for this study based on a statistical power of 80%.  A 
sample size of 13 for each group was determined to be adequate; however, due to the 
possibility of dropouts and outliers, a sample size of 25 for each group was used for this 
study. 
Inclusion Criteria 
1. Participants were healthy, premenopausal women aged 20-30 years and 35-45 
years. 
2. Women with normal menstrual cycles (10-14 cycles in 12 months). 
3. Body weight was less than 300 lbs (136.3 kg), which is the weight limit for 
DXA.  
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4. Height was less than 6 feet in order to get accurate values for both DXA and 
pQCT.  
Exclusion Criteria 
1. Women who were pregnant. 
2. Women taking medication that can affect bone density or metabolism, such as 
mineralocorticosteroids, glucocorticoids, bisphosphonates, and calcitonin. 
3. Women with an artificial knee, joint, or any other metal implantation in their 
bodies. 
4. Women with recent surgery, fracture, and open wounds. 
5. Women who had cardiovascular disease or uncontrolled hypertension. 
6. Women currently smoking or had smoked regularly within the past 6 months. 
7. Women with physical disabilities that prevent them from performing weight 
lifting exercises. 
Research Design 
This study was a non-randomized cross-sectional design with two independent 
groups: young women, 20-30 years, and middle-aged premenopausal women, 35-45 
years. There was no intervention for this study. The purposes of this study were to 
compare serum concentrations of sclerostin and DKK-1 in young (20-30 years) and 
middle-aged (35-45 years) premenopausal women. The present study also evaluated 
the differences in sclerostin and DKK-1 concentrations based on the physical activity 
status (low, moderate, and HEPA-active). This study further analyzed the relationship 
between bone density variables, jump trials and leg strength with the serum 
concentrations of sclerostin and DKK-1. This study required 3-4 visits to the Bone 
47 
Density Research Laboratory. During the first visit, each participant was instructed to 
complete the questionnaire regarding health, menstrual history, BPAQ, IPAQ, dietary 
calcium intake on a daily basis, physical activity readiness questionnaire (PAR-Q). 
Participants completed informed consent and HIPAA forms. These questionnaires 
provided information regarding medical history and exclusion criteria for each woman. 
These questionnaires asked about age, gender, levels of physical activity levels, lists of 
medicine taken over the past 6 months, and family history of cardiovascular diseases 
before the age of 50. During the second visit, a blood sample was drawn at Goddard 
Health Center to quantify the levels of sclerostin, DKK-1, and follicle-stimulating 
hormone (FSH). Serum FSH was measured only in the middle-aged women to confirm 
that they were not perimenopausal.  
During the third and fourth visits, both areal and volumetric bone density were 
assessed using DXA and pQCT. Following this, jump power and leg strength were 
assessed by using a jump mat and a leg press machine. To assess the test-retest 
reliability of the bone scans by DXA and pQCT, and the neuromuscular performance 
tests, a subset of 15 women were asked to return for the fourth visit (procedure were 
exactly the same as the third visit). We recently installed a new DXA machine in the 
Bone Density Research Laboratory, therefore we re-established the precision of the 
BMD variables measurements. Previous precision studies in this laboratory for pQCT 
and muscle performance variables had been done on young college-aged participants, 
which ensures that accurate high-quality data are collected across a wide variety of age 
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Bone-Specific Physical Activity Questionnaire (BPAQ) 
This questionnaire evaluated the current and past status of participant’s bone-
loading physical activities and sports. The questionnaire contained questions about the 
participant’s participation in sports activities within a year and the age at which they 
started to participate. It has been well established that osteogenic exercise influences 
bone adaptation by creating stress via muscle contraction (Turner and Robling, 2003). 
BPAQ was validated with other methods and is a good predictor of BMD, and its 
loading values were determined by measuring the ground reaction force for specific 
bone-loading activities (Beck and Weeks, 2008).  
Figure 3. Research Design 
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International Physical Activity Questionnaire (IPAQ) 
 This questionnaire contains 27 questions and is designed to yield scores to 
designate low, moderate and high intensity physical activity. Data for each activity 
(low, moderate, and high intensity) were converted metabolic equivalent task for 7 days 
(met-minutes.week-1) (Hagstromer, 2006). IPAQ has been well validated with other 
methods in assessing the physical activity scores (Craig et al., 2003). 
Calcium Intake Questionnaire 
 This questionnaire consisted of daily calcium intake information based on 
certain foods that are consumed in a day or a week by participants. The data allowed the 
researcher to calculate an estimation of the amount of calcium consumed daily based on 
the content of the specific foods. Participants provided information on any type of 
calcium supplements they were consuming along with their doses and generic names. 
The dietary calcium intake questionnaire was derived from a validated and quantitative 
food frequency questionnaire (Musgrave, 1989). 
Menstrual History Questionnaire 
 A menstrual history questionnaire was used to document participants’ menstrual 
cycle characteristics and hormonal contraceptive information such as dosage, type, and 
duration of use. Participants provided information on the length of the menstrual cycle, 
current menstrual status, length of flow, date of the last cycle, premenstrual syndrome, 
missed a period, and details on past history of taking hormonal contraception. This 
questionnaire also asked for information on the age at which her regular period started, 
amenorrhea in menstrual history, and any concern with hormonal abnormalities. 
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Anthropometric Measurements 
 Height was measured in centimeters with the individual standing with her back 
against the wall stadiometer (Novel products Inc., Rockton , IL) without shoes, head 
facing forward, arm at the side, heels against the wall, and holding her breath. Weight 
was measured in kilograms with minimal clothing, without shoes, and empty pockets 
via a digital weight scale (Tanita Corporation of America, Arlington Heights, IL).  
Areal Bone Mineral Density (aBMD) 
 DXA (GE Lunar Prodigy, Version 16, Madison, WI) was used to measure BMC 
(g) and aBMD (g/cm2) of the total body, anteroposterior (AP), lumbar spine (L1-L4), 
and dual proximal femur, which include femoral neck, trochanter, and total hip. Body 
composition variables such as percent body fat, fat mass, bone free lean body mass and 
fat free mass were also measured during the total body scan. The DXA scanner uses a 
filter-equipped X-ray tube, which converts polychromatic X-ray beams to low and high 
energy peaks. These attenuations are useful to provide the typical scan images. 
Participants were exposed to 0.05-1.5 mrem of radiation during the DXA scans, which 
is equivalent to spending one extra day in sunlight per year. Quality assurance testing 
(QA) was performed each day to ensure the proper operation of DXA. During the QA, a 
calibration block of known density was scanned to conduct a series of mechanical 
functioning tests performed by the software. These procedures were performed prior to 
scanning the first participant each day. The images from DXA are considered as 2D 
images; therefore, the thickness of the bone cannot be measured by DXA. 
 Additionally, each participant’s hydration status was measured from a urine 
sample with an optical refractometer (VEE GEE CLX-1, Rose Scientific Ltd., Alberta, 
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Canada) prior to the bone scans. This ensured hydration levels, as measured by urine 
specific gravity, were within the normal range of 1.004-1.029. It has been reported that 
hydration level could influence the accuracy of the body composition measurements. 
Therefore, participants with hydration status outside the range were rescheduled to 
return after normal hydration levels were established. A pregnancy test was performed 
using test strips (SAS Pregnancy Strip, SAS Scientific, San Antonio, TX) prior to the 
bone scans. The test strip was positioned at the top of the urine sample in a vertical 
position with arrows pointing downward, and not touching the stop line in the urine 
sample. The test was read after 4 minutes to check for positive or negative results. 
 During the DXA scans, participants laid in a supine position on the scanning 
table after removing their shoes and any metal or image-attenuating materials. For the 
total body scan, the participant remained in the supine position with hips and shoulders 
aligned to the center of the DXA table, with knees and ankles secured with Velcro 
straps. For the AP lumbar spine scans, the legs were supported on a foam block, which 
ensured a 45-90 degree angle at the hip joint and flattened the spine on the DXA table. 
Laser crosshairs were placed 3 cm below the umbilicus so that the iliac crest and T12 
vertebra were visible. Participants were instructed to cross their arms so that the upper 
arm was perpendicular to the DXA table. The scan progressed from L5 to T12 
vertebrae. The scan speed for the total body and lumbar spine was determined by 
measuring the thickness at the subject's naval (Thick = > 25 cm; Standard = 13-25 cm; 
and Thin = < 13 cm). The dual femur scan was performed by placing the feet in the foot 
brace so that the leg was internally rotated. This ensured the proper exposure of the 
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femoral neck and the femur in the scanning boundary. The laser crosshairs were placed 
7-8 cm below the trochanter so that the ischium was visible.  
 The software analyzed and performed all the necessary adjustments during 
scanning, depending upon the regions of interest (ROI) and either separate individual 
vertebrae or intervertebral markers. The in vivo precision and accuracy of the DXA 
RMS %CV in the Bone Density Research Laboratory is 0.7% for the total body BMD, 
1.4% for the spine, and 0.6% for total left and right hip BMD, 0.6% for right trochanter, 
0.7% for left trochanter, 0.9% for left femoral neck and 1.01% for left femoral neck. 
The in vivo precision of DXA RMS %CV for body composition variables is 2.0% for 
percent body fat and fat mass, 1.9% for bone free lean body mass, and 1.7% for fat free 
mass. 
Volumetric Bone Density (vBMD) Measurements 
 A pQCT XCT 3000 scanner with software version 6.00 (Stratec Medizintechnik 
GmbH, Pforzheim, Germany) was used to measure cortical vBMD (mg/cm3), BMC, 
(mg/mm), area (mm2); trabecular vBMD (mg/cm3), BMC (mg/mm), area (mm2), and 
total vBMD (mg/cm3) of 4%, 38%, and 66% of tibia sites. Compressive, bending and 
torsional strength was estimated as bone strength (BSI), stress-strain indices (SSI) 
(mm3), and moment of inertia (IP). The variables that indicate bone size and shape were 
measured as periosteal (Peri C) (mm) and endosteal circumference (Endo C) (mm).  
Calibration of the pQCT was done prior to the actual scan for each test day by a 
cone phantom. Participants’ information was entered into the computer after calibration. 
Prior to the scanning, participants’ tibia length of the non-dominant leg was measured 
from the tibia plateau to medial malleolus. Partcipants were instructed to place their 
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non-dominant leg into the gantry and to remain still throughout the scan. The scout 
view identified the reference point at the medial malleolus. Following this, 3 sets of 
scanning were performed at 4%, 38%, and 66% of the non-dominant tibia. The in vivo 
precision (RMS %CV) for the tibia ranges from 0.3-1.1% for the total bone variables, 
0.7-3% for trabecular bone variables, and 0.2-1.04% for the cortical bone variables was 
set in the Bone Density Research Laboratory (Appendix D).  
1RM Strength Testing 
 The leg press machine (Cybex, Medway, MA) was used for this study. Trained 
personnel instructed each participant on correct techniques for the two leg press. 
Following the instruction, participants practiced at light intensities to get accustomed to 
the machine. Participants were instructed to warm up for 3 minutes at a comfortable 
pace on a stationary bicycle ergometer (828E, Monark). Participants were then 
instructed to sit in a semi-reclined position on a Cybex two-leg press weight machine, 
where they completed a set of 5-10 with a load approximately equal to 50% of their 
estimated maximal strength. Following a 1 minute rest, participants then completed 3-5 
sets with a load approximately equal to 75% of their estimated maximal strength. Then, 
following about 2 minutes rest, loads were increased so that a maximal voluntary effort 
was achieved within 5 more attempts. The maximum effort is to define as the maximum 
load that subject could lift in a single attempt with a complete range of motion. Two 
minutes rest were given between the lifts, and the 1RM was obtained within 5 attempts. 
Jump Test Measurement 
Jump power and velocity were assessed by having the participants perform a 
jump test on the jump mat (Just Jump, Probotic, AL) with a Tendo FiTRODYNE power 
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and a speed analyzer (Tendo Sports Machines, Trencin, Slovak Republic). 
Familiarization was done prior to the actual test, where participants practiced to get 
accustomed to the countermovement jump.  
Participants’ body weight with their shoes and transfer belt on was measured. 
Participants were asked to step on the mat, stand with feet shoulder-width apart, and 
performed 3 countermovement vertical jumps by crouching, then jumping with non-
restricted arm motion, and then landing on the jump mat. The power (watts) and jump 
velocity (meters/second) from the Tendo machine, and the time in the air (seconds) and 
jump height (inches) from the Just Jump device were recorded. A minimum of 1 minute 
rest or as long as the subject needed was allowed between jumps. Trained spotters stood 
on either side of the participant to help with balance if needed. Additionally, a transfer 
belt was fastened around the waist of the participant that was held by the spotter to 
stabilize the participant if she lost her balance. A total of 3 counter movement jumps 
were recorded for each participant and the average of the 3 trials for all the variables 
were used for data analyses. The precision for jump performance and 1RM strength 














Table 1. Precision for Jump Test Variables (n=15) 
Variable ICC CV% 
Jump Power (watts) 0.94 3.74% 
Jump velocity (m/s) 0.80 4.40% 
Air Time (sec) 0.96 2.06% 
Vertical Jump Height (inches) 0.97 3.06% 
1RM Strength (kg) 0.98 1.94% 
 
Blood Sampling and Biochemical Assays 
 A blood sample (7.5 ml) was collected via venipuncture by a phlebotomist at the 
Goddard Health Center in the morning (8:00-9:00 am). Participants were instructed to 
fast for 8 hours before the blood collection. Blood samples were allowed to clot, 
centrifuged and serum samples were transferred into 6 microtubes. The plasma samples 
were kept frozen at -84ºC prior to the assays.  
 Prior to each assay, the frozen serum samples and all kits reagents were taken 
out of the freezer and allowed to reach room temperature. Thawing of the frozen 
samples was done only once to avoid protein denaturation. Commercial Enzyme-Linked 
TECO medical Immunoassay Kit (Quidel Corp., Santa Clara, CA) was used to measure 
serum levels of sclerostin. Human DKK-1 ELISA (Eagle Biosciences, Inc, Nashua, 
NH) was used to measure serum levels of DKK-1. Serum FSH (Alpco, Salem, NH) was 
measured to confirm the perimenopausal status only in middle-aged women. We found 
FSH concentrations were less than 15 IU/L, confirming that all subjects were 
premenopausal women.  
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 Step-by-step protocols were followed per assay kit instruction manuals (see 
Appendix G). Standard precautions were applied when handling bodily fluids. Assay 
precision was determined by measuring control samples at the beginning and end of 
each assay (intra-assay) and by measuring the same control sample in each assay run 
(inter-assay). For good precision, both intra- and inter-assay coefficients of variation 
(CV%) should be less than 10%. In this study, the intra- and inter-assay CVs for 
sclerostin were 3.7 and 8.3%; the intra- and inter-assay CVs for DKK-1 were 4.9 and 
5.1%, respectively. 
Data Analyses 
 Data were analyzed using IBM SPSS 23.0 (SPSS Inc., Chicago, IL). All 
descriptive statistics are reported as means ± standard deviation (SD) unless otherwise 
stated. All dependent variables were tested for normality using the Kolmogorov-
Smirnov test. Two-way ANOVA (age × physical activity status) was used to determine 
the effects of age and physical activity status on sclerostin and DKK-1. If confounding 
variables such as body weight, height, and BMC were significantly different between 
the age groups (as determined by independent t-tests), then these variables were used as 
covariates in ANCOVAs. Zero-order Pearson Product Moment correlation coefficients 
were computed to determine the relationships between sclerostin/DKK-1 and aBMD, 
vBMD, leg strength, and jump power, respectively, for all 50 participants combined. 
Intraclass correlation coefficients (ICC) were calculated for jump test and leg press 
variables. The level of significance was set at p ≤ 0.05.  
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Chapter 4: Results and Discussion 
The purpose of this study was to compare serum concentrations of sclerostin and 
DKK-1 in young (20-30 years old) and middle-aged (35-45 years old) premenopausal 
women. These age groups were selected to allow comparisons between women who are 
still accruing bone mass versus those who have already achieved their peak bone mass. 
The present study also evaluated the differences in sclerostin and DKK-1 concentrations 
based on the physical activity status (low, moderate, and HEPA-active). Dependent 
variables included the Wnt signaling inhibitors, sclerostin and DKK-1, and BMD and 
BMC of total body, lumbar spine, and dual femur. This study also measured vBMC and 
vBMD of non-dominant tibia (4%, 38%, and 66%) sites. Additional variables included 
components of hip structural analysis (HSA), and lower body strength (leg press) and 
jump power. The secondary purposes of this study were to evaluate sclerostin and 
DKK-1 relationships with aBMD, vBMD, HSA variables, and muscle performance 
variables.  
Participants 
In this cross-sectional study, participants were premenopausal women in the age 
groups of 20-30 and 35-45 years. A total of 57 women responded to study 
advertisements and were screened for eligibility. Five women were excluded prior to 
enrollment due to irregular menstruation or medications, and 2 women were lost to 
follow-up. A total of 50 young (n=25) and middle-aged (n=25) women participated in 
this study and completed all protocols. Participants were recruited from the University 
of Oklahoma, Norman, and surrounding areas. Recruitment methods for this study 
include flyers, mass email, and word-of-mouth. Participants also reported the details on 
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past history of taking hormonal contraception. Based on this information, participants 
were further categorized into two groups: hormonal contraceptive users (HC users) 
(n=14) and non-users (n=36). Of the 14 contraceptive-using participants, 8 participants 
were using oral contraceptives with dosages of estradiol greater than 20 µg, 5 were 
using an intrauterine device, and 1 reported using depo injection.  
Table 2 summarizes the physical characteristics of participants for the two age 
groups. There was a trend for young women being taller than middle-aged women 
(p=0.052). The total physical activity scores were not significantly different between 
age groups (p>0.46). Since there were no statistically significant differences for 
confounding variables such as height, weight, percent body fat, fat mass, fat-free mass 















Table 2. Physical Characteristics for Young and Middle-aged Groups (Mean ± SD) 
Variable Young (n=25) Middle-Aged (n=25) 
Age (yrs)* 25.56 ± 3.35 39.00 ± 2.49 
Height (cm) 167.56 ± 5.45 164.43 ± 5.66 
Weight (kg) 67.16 ± 13.23 66.21 ± 12.30 
Calcium Intake  (mg/day) 902 ± 411 875 ± 387 
pBPAQ Score 55.58 ± 48.67 55.42 ± 56.24 
cBPAQ Score 7.11 ± 8.57 14.56 ± 26.20 
Total PA Score (mets/min) 3241.98 ± 2671.95 3783.64 ± 2578.51 
Body Fat % 31.47 ± 6.66 34.08 ± 9.05 
Fat Mass (kg) 20.85 ± 8.09 24.85 ± 12.23 
BFLBM (kg) 43.95 ± 7.31 41.46 ± 5.91 
Fat Free Mass (kg) 46.42 ± 7.55 43.82 ± 6.14 
* p<0.05 significant age difference; pBPAQ= past Bone Specific Physical Activity 
Questionnaire; cBPAQ= current Bone Specific Physical Activity Questionnaire; Total PA 
Score= Total Physical Activity Score; BFLBM= Bone Free Lean Body Mass.  
 
Physical Activity, Serum Sclerostin, and Serum DKK-1  
The current study utilized IPAQ to assess physical activity scores. The three 
levels of physical activity were low (less than 600 MET-min/week), moderate (MET-
min/week between 600 and 2,999 MET-min/week), HEPA-active (more than 3000 
MET-min/week). In the current study, only three participants self-reported as a low-
level physical activity, therefore, we combined low and moderate activity together. 
Two-way ANOVA was used to determine whether there was an interaction between age 
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group and physical activity status on sclerostin and DKK-1 levels. Serum sclerostin 
concentrations were significantly higher in middle-aged women compared to young 
women (p<0.001) (Table 3, Figure 4). The mean values of sclerostin for young and 
middle-aged were 0.41 ± 0.01 ng/ml and 0.54 ± 0.01 ng/ml, respectively (Figure 4), 
which is within the range expected for premenopausal women according to the assay kit 
(Appendix F). There was also a significant main effect for physical activity levels 
(p<0.05), with serum sclerostin concentrations being significantly higher in HEPA–
active women compared to low-moderate active women (Table 3). However, there was 
no age × physical activity level interaction for sclerostin concentrations (p>0.05). Since 
total body aBMD was higher in HEPA-active women compared to low-moderately 
active women, total body aBMD was used as a covariate, which eliminated the main 
effect for physical activity levels (p= 0.11).  
Serum DKK-1 concentrations were not significantly different between age 
groups or based on physical activity classifications (p>0.05). The mean values of serum 
DKK-1 for young and middle-aged women were 54.25 ± 3.2 pmol/l and 48.77 ± 3.2 
pmol/l, respectively (Table 3, Figure 5). Serum DKK-1 concentration ranged from 
15.53 to 86.16 pmol/l. Due to lack of literature on the normal ranges, we are not able to 
compare our DKK-1 ranges with other studies.  
Independent t-tests were used to assess differences between HC users and non-
users in sclerostin and DKK-1 levels. There was a significant difference between HC 
users and non-users for both sclerostin and DKK-1 concentrations (p<0.05). The mean 
values of sclerostin for HC users (n=14) and non-users (n=36) were 0.42 ± 0.02 ng/ml 
and 0.50 ± 0.01 ng/ml, respectively. The mean values for DKK-1 levels for HC users 
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(n=14) and non-users (n=36) were 42.38 ± 3.9 and 55.06 ± 2.6 pmol/l, respectively. We 
also compared differences between oral contraceptive users (OC users) (n=8) and non-
users (n=42) and found that there were significant differences between the two groups 
for sclerostin concentrations (p=0.05) and no significant differences for DKK-1 






Figure 4. Serum Sclerostin Concentrations in Young (n=25) and Middle-aged 













Figure 5. Serum DKK-1 Concentrations in Young (n=25) and Middle-aged (n=25) 






Table 3. Serum Sclerostin and DKK-1 Based on Age and Physical Activity Levels 
(Mean ± SD) 









Sclerostin (ng/ml)**† 0.38 ± 0.77 0.44 ± 0.06 0.51 ± 0.09 0.56 ± 0.01 
DKK-1 (pmol/l) 55.36 ± 17.14 53.05 ± 14.99 48.70 ± 17.95 48.84 ± 16.52 
** Significant age effect p<0.01; † Significant physical activity effect p<0.05 
Areal Bone Mineral Density 
Two-way ANOVA was used to determine if there was an interaction between age group 
and physical activity levels on aBMD variables. There were significant main effects for 
age (p<0.05) and physical activity levels, however, there was no age × physical activity 
levels interaction observed for aBMD variables. Both age groups had average Z-Scores 
above -2.0 for total body and spine. However, one participant had a Z-Score below -2.0 
for right trochanter aBMD.  
There was a significant main effect of physical activity levels for total body 
aBMD, total body Z-scores, and spine aBMD (p<0.05), with HEPA-active women 
having higher mean values for total aBMD, total body Z-Score, and spine L1-L4 aBMD 
(Table 4). There was also a significant main effect of age for spine BMC, with the 
young group having significantly higher BMC than middle-aged women (p<0.05). 
However, there were no significant age × physical activity level interactions for total 
body and lumbar spine aBMD variables. There were significant main effects of physical 
activity levels for of all the hip aBMD variables (p<0.05). HEPA-active women had 
significant higher values for hip aBMD variables compared to low-moderate active 
women (p<0.05) (Table 5). There was also a significant main effect of age for left 
trochanter aBMD, with the young group having significantly higher left trochanter 
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aBMD than middle-aged women (p<0.05). There were no significant age × physical 
activity level interactions for hip aBMD variables. 
Table 4. Total Body and Lumbar Spine Areal Bone Mineral Density (Mean ± SD) 
 
*Significant age effect p<0.05; † Significant physical activity effect p<0.05; aBMD= areal Bone 
Mineral Density. 
.  









Total Body aBMD (g/cm
2
)† 1.192 ± 0.555 1.262 ± 0.086 1.188 ± 0.108 1.221 ± 0.082 
Total Body BMC (g) 2427.38 ± 195.30 2554.41 ± 337.80 2337.16 ± 320.43 2377.61 ± 331.79 
Total Body Z-Scores † 1.01 ± 0.60 1.51 ± 0.54 0.94  ± 1.13 1.40 ± 0.72 
Spine L1-L4 aBMD (g/cm
2
)† 1.228 ± 0.078 1.346 ± 0.129 1.235 ± 0.122 1.255 ± 0.126 
Spine L1-L4 BMC* 68.04 ± 6.45 73.51 ±10.50 64.83 ± 10.22 65.65 ± 10.41 
Spine L1-L4 Z-Scores 0.34 ± 0.76 1.25 ± 1.21 0.37 ± 1.10 0.60 ± 0.97 
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Table 5. Hip Areal Bone Mineral Density (Mean ± SD)  
 
* Significant age effect p<0.05; † Significant physical activity effect p<0.05; BMD= Bone 
Mineral Density; Troch= Trochanter; FN= Femoral Neck; THIP= Total Hip 
 
Volumetric Bone Mineral Density 
The variables measured by pQCT were total volumetric BMC, total volumetric BMD, 
trabecular BMD, trabecular volumetric BMD, total area, trabecular area, periosteal 
circumference, endosteal circumference, stress-strain index, cortical volumetric BMC, 
cortical volumetric BMD, and polar moment of inertia at 4%, 38% and 66% of the non-
dominant tibia. Muscle cross-sectional area was also measured at 66% of the non-dominant 
tibia.  
Two-way ANOVA was used to determine the effects of age group and physical activity 
status on pQCT bone density variables. There were significant main effects for age; 










Right FN aBMD (g/cm
2
) † 1.009 ± 0.087  1.122 ± 0.085  0.984 ± 0.136   1.053 ± 0.100 
Left FN aBMD (g/cm
2
) † 1.018 ± 0.088  1.116 ± 0.083  0.993 ± 0.161   1.054 ± 0.099 
Right FN Z-Scores†  -0.27 ± 0.58    0.50 ± 0.70   -0.06 ± 0.99     0.51 ± 0.73 
Left FN Z-Scores†  -0.20 ± 0.50    0.41 ± 0.66    0.00 ± 1.15     0.52 ± 0.75 
Right Troch aBMD (g/cm
2
) † 0.811 ± 0.069  0.898 ± 0.076  0.778 ± 0.119   0.856 ± 0.089 
Left Troch aBMD (g/cm
2
) *† 0.816 ± 0.067  0.887 ± 0.082  0.758 ± 0.126   0.833 ± 0.086 
Right Troch Z-Scores  †             -0.40 ± 0.60                  0.33 ± 0.76   -0.49 ± 1.05     0.25 ± 0.81 
Left Troch Z-Scores  †             -0.38 ± 0.52                 0.26 ± 0.74   -0.65 ± 1.09     0.06 ± 0.83 
Left THIP aBMD (g/cm
2
) † 1.025 ± 0.089  1.105 ± 0.074   0.984 ± 0.150   1.054 ± 0.080 
Right THIP aBMD (g/cm
2
) †  0.811 ± 0.069  0.898 ± 0.076   0.778 ± 0.119   0.856 ± 0.089 
Right THIP Z-Scores  †             -0.04 ± 0.64                 0.77 ± 0.66     0.07 ± 1.02     0.73 ± 0.71 
Left THIP  Z-Scores   †             0.05 ± 0.60              0.64 ± 0.66   -0.04 ± 1.12     0.59 ± 0.68 
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however, there were no significant main effects for physical activity status or age × physical 
activity level interactions for pQCT bone density variables. Table 6 shows significant main 
effects for age for total volumetric BMC, trabecular BMC and BMD, and trabecular bone 
strength index at the 4% tibia site (p<0.05), which were higher in young women compared to 
middle-aged women.  
Table 7 shows that there was a significant main effect of age for cortical vBMD at the 
38% tibia site (p<0.05). Middle-aged women had significantly higher cortical vBMD than 
young women (p<0.05). There were no significant main effects for physical activity levels 
and also no significant age × physical activity interaction for 38% pQCT bone 
characteristics. Table 8 shows that there was a significant main effect of age for total area, 
Peri C, SSI, and IPolar at the 66% tibia site (p<0.05). Young women had significantly 
greater total area, Peri C, SSI and IPolar compared to middle-aged women (p<0.05). There 
were no significant main effects for physical activity level and also no significant age × 
physical activity interactions for 66% pQCT bone characteristics. 
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Table 6. pQCT 4% Bone Characteristics of the Non-dominant Tibia (Mean ± SD)  
 
* Significant age effect p<0.05; ** Significant age effect p<0.001; vBMD= volumetric Bone 
Mineral Density; Trab= Trabecular; vBMC= volumetric Bone Mineral Content; Peri C= 
Periosteal Circumference; BSI= Bone Strength Index 
  










Total vBMC (mg/mm) *   294.07 ± 39.20  323.04 ± 46.26     277.44 ± 50.05   281.83 ± 41.06 
Total vBMD (mg/cm
3
) 304.046 ± 34.380  317.475 ± 30.536 287.041 ± 27.047 310.023 ± 37.503 
Trab BMC (mg/mm) *   212.73 ± 36.81     233.23 ± 39.02   194.94 ± 38.24   194.45 ± 34.51 
Trab vBMD (mg/cm
3
) * 253.907 ± 35.037   269.475 ± 32.293 233.233 ± 23.522  249.876 ± 38.410 
Total Area  (mm
2
)   969.04 ± 89.84   1020.92 ± 137.47   962.18 ± 105.94    910.32 ± 97.47 
Trab Area  (mm
2
)   838.21 ± 85.76    880.79 ± 126.75   830.61 ± 93.31    778.60 ± 88.99 
Peri C (mm)   109.63 ± 6.05    113.02 ± 7.78   109.80 ± 6.01    106.81 ± 5.78 
BSI  (mg*mm)                90.30 ± 20.97                  103.08 ± 20.90     80.68 ± 21.81      88.42 ± 21.96 
Trab BSI (mg*mm)**                 55.61 ± 16.62                  64.34 ± 14.97     46.20 ± 13.87      49.58 ± 14.93 
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Table 7. pQCT 38% Bone Characteristics of the Non-dominant Tibia (Mean ± SD)  
 
* Significant age effect p<0.05; vBMD= volumetric Bone Mineral Density; vBMC= volumetric 
Bone Mineral Content; Cort= cortical; Peri C= Periosteal Circumference; Endo C= Endosteal 
Circumference; SSI= Stress Strain Index; IPolar= Polar Moment of Inertia of the Cortical Bone 
 










Total vBMC (mg/mm)     350.65 ± 52.98  358.94 ± 55.80      324.33 ± 41.26      342.04 ± 47.04 
Total vBMD (mg/cm
3
)   950.223 ± 76.200  960.041 ± 51.449   947.358 ± 91.100    975.492 ± 36.466 
Total Area  (mm
2
)     368.59 ± 45.51     373.60 ± 50.91     353.46 ± 50.86      350.85 ± 47.95 
Peri C (mm)       67.93 ± 4.25       68.36 ± 4.73       65.55 ± 2.87        66.25 ± 4.64 
Endo C (mm)                  33.00 ± 4.78                     32.11 ± 3.70       32.03 ± 5.28        31.05 ± 2.86 
Cort vBMC (mg/mm)     334.70 ± 51.51     346.91 ± 54.52     312.44 ± 41.89      330.58 ± 45.93 
Cort vBMD* 1194.684 ± 19.640 1195.108 ± 15.482 1206.775 ± 26.952   1209.453± 13.983 
Cort Area   280.209 ± 42.74    290.50 ± 46.83     258.90 ± 34.28     273.48 ± 38.97 
SSI (mm
3
)   1560.23 ± 290.96  1617.98 ± 313.06   1418.00 ± 182.01 1481.689 ± 279.10 
IPolar (mm
4
)   23298.9 ± 562.7  24505.5 ± 7214.8   20173.5 ± 3661.1   21604.9 ± 5559.3 
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Table 8. pQCT 66% Bone Characteristics of the Non-dominant Tibia (Mean ± SD) 
 
*Significant age effect p<0.05; vBMD= volumetric Bone Mineral Density; vBMC= volumetric 
Bone Mineral Content; Cort= cortical; Peri C= Periosteal Circumference; Endo C= Endosteal 
Circumference; SSI= Stress Strain Index; IPolar= Polar Moment of Inertia of the Cortical Bone; 
MSCA= Muscle Cross-Sectional Area 
 
Hip Structural Analyses 
The measurement variables for hip structural analyses included right and left SI, 
BR, SM, and CSMI.  
Two-way ANOVA was used to determine the effects of age group and physical 
activity status on hip structural analyses variables. Table 9 shows that a significant main 
effect of age was observed for left SM (p<0.05). Middle-aged women had significantly 
lower SM compared to young women (p<0.05). There were also significant main effects 
of age (p<0.05) and physical activity level (p<0.01) for right BR. Middle-aged women 










Total vBMC (mg/mm)     378.12 ± 47.69  377.29 ± 63.71      350.66 ± 44.13    353.22 ± 59.49 
Total vBMD (mg/cm
3
)   698.700 ± 54.307  696.842 ± 58.352   708.833 ± 78.109  732.077 ± 102.475 
Total Area  (mm
2
)*     542.80 ± 70.86     543.13 ± 92.38     497.44 ± 49.66     501.03 ± 63.83 
Peri C (mm)*       82.42 ± 5.40       82.33 ± 7.09       78.89 ± 3.98       79.17 ± 5.38 
Endo C (mm)                  55.55 ± 5.41                55.13 ± 6.60       52.57 ± 5.13       52.60 ± 5.06 
Cort vBMC (mg/mm)     341.16 ± 42.63     341.61 ± 55.61     319.87 ± 41.79     323.78 ± 54.11 
Cort vBMD 1156.546 ± 22.274 1148.467 ± 22.026 1164.817 ± 28.665 1161.608 ± 17.160 
Cort Area     295.07 ± 36.89     298.01 ± 51.20     274.60 ± 35.31     278.94 ± 47.38 
SSI (mm
3
)*   2347.68 ± 440.48   2434.80 ± 574.20   2088.79 ± 290.81  2140.60 ± 411.16 
IPolar (mm
4
)*   42757.9 ± 9987.9   43968.3 ±13883.3   36204.1 ± 6845.7  37694.6 ± 9923.7 
MSCA    6364.42 ± 941.00  7253.52 ± 1506.85   6616.92 ± 1231.5  6843.48 ± 1365.79 
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had significantly higher BR compared to young women (p<0.05) and HEPA-active 
women had significantly lower BR compared to low-moderately active women 
(p<0.01). However, there were no age × physical activity level interactions for hip 
structural analyses variables. 
Table 9. Hip Structural Analyses (Mean ± SD) 
 
* Significant age effect p<0.05; †† Significant physical activity levels p<0.001; SI= Strength 
Index; SM= Sectional Modulus; BR= Buckling Ratio; CSMI= Cross-sectional Moment of 
Inertia. 
 
Muscle Function Assessment 
The measurement variables for muscle function were jump performance and 
1RM leg strength. The jump performance variables were time in air, velocity, vertical 
jump height, jump power and relative jump power.  
Two-way ANOVA was used to determine the effects of age group and physical 
activity status on muscle function assessment. A significant main effect of age was 
observed for time in air, jump height, relative jump power, and 1RM (p<0.05), with 
middle-aged women having significantly lower values compared to young women 










Right SI         1.59 ± 0.53 1.73 ± 0.39 1.40 ± 0.28 1.63 ± 0.36 
Left SI       1.63 ± 0.34   1.72 ± 0.43 1.50 ± 0.38 1.56 ± 0.37 
Right SM (mm
3
)       659.12 ± 110.87    702.56 ± 138.86 614.98 ± 110.29 614.53 ± 116.30 
Left SM (mm
3
)*     651.60 ± 84.35    714.91 ± 139.36 627.12 ± 129.90 593.78 ± 93.85 
Right BR*††                 3.04 ± 0.68    2.05 ± 0.52 3.40 ± 1.22    2.98 ± 0.99 
Left BR             2.90 ± 0.98    2.86 ± 1.07 3.11 ± 1.14    3.40 ± 1.00 
Right CSMI (mm
4
)    10310.00 ± 2798.03       10671 ± 2924.34    9397.16  ± 2188.16  9393.84 ± 2151.18 
Left CSMI (mm
4
)     9914.53 ± 1898.80  11041.83 ± 2857.46 9690.83 ± 2457.32  8986.53 ± 1565.10 
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(p<0.05). There was no main effect of physical activity level and no age × physical 
activity level interactions for those variables.  
Table 10. Muscle Performance Variables (Mean ± SD)  
 
* Significant age effect p<0.05; ** Significant age effect p<0.001; Rel =Relative 
 
Correlations 
Zero-order Pearson Product Moment correlation coefficients were computed to 
determine the relationships of sclerostin and DKK-1 levels with aBMD, vBMD, hip 
structural analyses, and muscle strength variables. Generally, all the correlation values 
were significantly low except for the cortical vBMD at the 38% tibia site (r=0.5). There 
was also a trend of a low positive relationship between serum concentrations of 
sclerostin and DKK-1 (r= 0.22; p=0.058). 
There were significant but low positive relationships between total body Z-
score, spine BMD, and spine Z-Scores with serum sclerostin concentrations (p<0.05) 
(Table 11). Similarly, significant but low positive relationships were found for spine 
BMD and spine Z-Scores with serum DKK-1 concentrations (p<0.05). 
There were significant but low positive relationships observed between right 
neck Z-score, left neck Z-score, right trochanter BMD, right trochanter Z-score, left 









Time in air (s)**      0.51 ± 0.06     0.53 ± 0.05   0.47 ± 0.05     0.47 ± 0.06 
Jump height (inches)**     13.43 ± 3.10      14.13 ± 2.69       11.12 ± 2.52   11.20 ± 3.33 
Velocity (m/s)      0.99 ± 0.13  1.04 ± 0.09  0.94 ± 0.13    0.92 ± 0.09 
Jump Power (watts)  647.40 ± 107.99  698.13 ± 141.61  622.91 ± 142.39    593.20 ± 127.62 
Rel Jump Power (watts/kg)*              9.85 ± 1.30      11.44 ± 3.69  9.22 ± 1.49    9.17 ± 1.02 
1RM (kg)*  125.17 ± 25.07    144.29 ± 36.90 113.24 ± 20.18 121.67 ± 29.23 
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trochanter Z-score, total right BMD, total left Z-score, and total right Z-Score with 
serum sclerostin concentrations (p<0.05) (Table 12). Similarly, significant low positive 
relationships were found for right trochanter BMD, left trochanter BMD, right 
trochanter Z-score, and left trochanter Z-score with serum DKK-1 concentrations 
(p<0.05). There were no significant correlations for sclerostin and DKK-1 with hip 
structural analyses variables (p>0.05). Similarly, no significant correlations were found 
for 4% pQCT bone variables with sclerostin and DKK-1 (p>0.05) (Appendix E).  
There were significant but low negative relationships observed for total area, 
periosteal circumference, and endosteal circumference at 38% tibia site with serum 
sclerostin concentrations (p<0.05) (Table 13). There was also a moderate positive 
relationship between cortical vBMD and serum sclerostin concentrations (p<0.001). 
There were no significant relationships between 38% pQCT variables and serum DKK-
1 concentrations (p>0.05). 
There was a significant but low positive relationship between cortical vBMD at 
the 66% tibia site and serum sclerostin concentrations (p<0.01) (Table 14). There was 
no significant association between 66% tibia variables and serum DKK-1 
concentrations. 
There was a significant but low negative relationships between time in air and 
vertical jump height with serum sclerostin concentrations (p<0.05) (Table 15). No 




Table 11. Correlations between Serum Sclerostin and DKK-1 Concentrations with 
Total Body and Lumbar Spine Areal BMD Variables 
Variables r Variables r 
Serum sclerostin  Serum DKK-1  
Total Body BMD 0.18 Total Body BMD 0.11 
Total Body BMC 0.05 Total Body BMC 0.14 
Z-Score 0.28* Z-Score 0.01 
Spine L1-L4 BMD 0.31* Spine L1-L4 BMD 0.28* 
Spine L1-L4 BMC 0.16 Spine L1-L4 BMC 0.22 
Spine L1-L4 Z-Score 0.36* Spine L1-L4 Z-Score 0.25* 
















Table 12. Correlations between Serum Sclerostin and DKK-1 Concentrations with 
Hip Areal BMD Variables. 
Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Right Neck BMD 0.22 Right Neck BMD 0.11 
Left Neck BMD 0.21 Left Neck BMD 0.09 
Right Neck Z-Score 0.46* Right Neck Z-Score 0.09 
Left Neck Z-Score 0.44* Left Neck Z-Score 0.06 
Right Trochanter BMD 0.25* Right Trochanter BMD 0.27* 
Left Trochanter BMD 0.16 Left Trochanter BMD 0.26* 
Right Trochanter Z-Score 0.36* Right Trochanter Z-Score 0.27* 
Left Trochanter Z-Score 0.30* Left Trochanter Z-Score 0.26* 
Total Left BMD 0.15 Total Left BMD 0.18 
Total Right BMD 0.25* Total Right BMD 0.14 
Total Left Z-Score 0.32* Total Left Z-Score 0.16 
Total Right Z-Score 0.42** Total Right Z-Score 0.12 











Table 13. Correlations between Serum Sclerostin and DKK-1 Concentrations with 
38% pQCT Variables. 
Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Total BMC -0.09 Total BMC 0.11 
Total vBMD 0.26* Total vBMD 0.10 
Total Area -0.24* Total Area 0.11 
Periosteal Circumference -0.24* Periosteal Circumference 0.06 
Endosteal Circumference -0.31* Endosteal Circumference -0.03 
Cortical BMC -0.05 Cortical BMC 0.11 
Cortical vBMD 0.50** Cortical vBMD 0.19 
Cortical Area -0.10 Cortical Area 0.09 
Stress-Strain Index -0.15 Stress-Strain Index 0.14 
IPolar -0.18 IPolar 0.11 
*p<0.05; **p<0.01; vBMD= Volumetric Bone Mineral Density; vBMC= volumetric Bone 












Table 14. Correlations between Serum Sclerostin and DKK-1 Concentrations with 
66% pQCT Variables. 
Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Total BMC -0.13 Total BMC 0.13 
Total vBMD 0.12 Total vBMD 0.04 
Total Area -0.20 Total Area 0.09 
Periosteal Circumference -0.20 Periosteal Circumference 0.08 
Endosteal Circumference -0.18 Endosteal Circumference 0.02 
Cortical BMC -0.09 Cortical BMC 0.14 
Cortical vBMD 0.34** Cortical vBMD 0.17 
Cortical Area -0.13 Cortical Area 0.11 
Stress-Strain Index -0.15 Stress-Strain Index 0.11 
IPolar -0.16 IPolar 0.14 
Muscle Cross Sectional Area 0.31 Muscle Cross Sectional Area 0.02 
**p<0.01; vBMD= Volumetric Bone Mineral Density; BMC= Bone Mineral Content; IPolar= 










Table 15. Correlations between Serum Sclerostin and DKK-1 Concentrations with 
Muscle Performance Variables  
Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Time in air -0.27* Time in air -0.15 
Vertical Jump height -0.27* Vertical Jump height -0.02 
Velocity -0.20 Velocity -0.04 
Power -0.18 Power 0.03 
1RM -0.06 1RM 0.16 

















The current study was designed to investigate the serum concentrations of 
sclerostin and DKK-1 in young and middle-aged premenopausal women. The selection 
of these age ranges allowed us to compare these two Wnt inhibitors between women 
who were still accruing bone mass versus those who had already achieved their peak 
bone mass. The present study also evaluated the differences in the sclerostin and DKK-
1 concentrations based on physical activity status: low-moderate versus HEPA-active. 
Furthermore, this study evaluated the relationships between serum sclerostin and DKK-
1 with several BMD and muscle performance variables. The unique characteristic of 
this study was the investigation of Wnt signaling inhibitor levels with respect to peak 
bone mass. The results showed significant differences in sclerostin levels based on peak 
bone mass and physical activity level. Sclerostin and DKK-1 levels and their 
relationships to mechanical loading have been well documented in previous animal 
model studies. However, human research is limited and there have been conflicting 
results. The findings from the current investigation provide insights into the 
relationships between Wnt signaling inhibitor characteristics, peak bone mass, and 
physical activity in premenopausal women.  
 It is well documented that mechanical loading or physical activity influence 
bone remodeling processes through the activation of osteoblasts and osteoclasts; more 
recent findings also implicate a regulatory role of osteocytes in this process. Osteocytes 
are the principle cells in integrating mechanical and chemical signals. Sclerostin and 
DKK-1 are exclusively found in osteocytes and act as negative regulators of bone 
metabolism. Therefore, understanding mechanical loading or physical activity and 
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expression of sclerostin and DKK-1 provides important cues for skeletal 
mechanoregulation. 
Age, Physical Activity, and Wnt Signaling Inhibitors 
The Wnt signaling pathway is fine-tuned by several secreted glycoproteins such 
as sclerostin and DKK-1, which bind to the LRP5/6 receptor and disrupt the canonical 
Wnt signaling pathway. This signaling pathway is an important regulator of skeletal 
adaptation based on individual biomechanical demands. In animal models, mechanical 
stimulation of bone effectively decreases osteocyte production of sclerostin and DKK-1 
in a dose-dependent manner, while their levels are increased during unloading or bed 
rest condition (Robling et al., 2006; Gaudio et al., 2012).   
The major finding from the current study is that serum sclerostin levels were 
significantly higher in middle-aged women compared to young women, which is in line 
with the previous study by Modder et al. (2010), where serum sclerostin concentrations 
significantly increased with age. The previous study had larger sample size compared to 
the current study and men had significantly higher levels of sclerostin than women. The 
authors explained that the higher serum sclerostin in men could possibly be due to 
higher skeletal mass, as total body BMC was significantly higher in men. In the present 
study, men were excluded and no significant differences were observed for total body 
BMC and BFLBM between the two age groups of women. 
Another study reported that sclerostin levels increased linearly with age, and that 
postmenopausal women had significantly higher sclerostin levels than premenopausal 
women (Ardawi et al., 2011). Age-related impairment in bone formation and decreased 
renal function could be possible mechanisms accounting for the increased circulating 
80 
levels of sclerostin with aging. Furthermore, aging is associated with an increase in 
oxidative stress via the FoxO mediated pathway, which could possibly lead to 
attenuation of Wnt proteins and osteoblasts, thus increasing serum sclerostin levels 
(Manolaga, 2007; Lopez-Otin, 2013).    
Only a few studies in humans have explored circulating DKK-1 levels (Gaudio 
et al., 2010; Tian et al., 2015), thus necessitating exploring animal studies to understand 
Wnt signaling inhibitors in human skeletal metabolism. The evidence from animal 
studies using overexpressed DKK-1 and DKK-1 haploinsufficient mice suggest that 
DKK-1 is a potent inhibitor of bone formation (Li et al., 2006; Morvan et al., 2006). 
Furthermore, animal studies suggest that DKK-1 levels were very low in healthy tissue 
compared to necrotic tissue (Kinsley et al., 2015). 
The current study found no significant differences in serum DKK-1 between the 
two age groups. In contrast, Dovjak et al. (2014) compared DKK-1 in young and older 
men and women and found that DKK-1 levels were higher in older men and women 
compared to younger individuals, suggesting the importance of Wnt inhibitors with 
aging. Tian et al. (2015) showed that serum DKK-1 levels were significantly higher in 
osteoporotic postmenopausal women compared to healthy postmenopausal women, 
suggesting a potential role of DKK-1 in skeletal metabolism and the Wnt signaling 
pathway. Participants in the current study were younger and were from diverse ethnicity 
compared to those investigated by Tian et al. (2015), possibly explaining disagreement 
between the two studies.  
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Evidence suggests that the effects of mechanical loading on bone mass is 
mediated by the effects of resident bone cells (osteoblasts, osteoclasts, and osteocytes). 
The abundance and strategic location of osteocytes make them favorable for detecting 
mechanical signals that lead to bone adaptation (Delgado-Calle et al., 2017).  It has 
been reported that expression of sclerostin is higher in mature osteocytes and its 
expression is decreased in the presence of mechanical loading (Robling et al., 2006).  
An immunohistochemical study on C57BL/6 mice showed that dynamic axial 
loading is associated with downregulation of sclerostin expression in osteocytes and 
increased bone volume and bone formation (Moustafa et al., 2011). The results from the 
current study showed that sclerostin levels were significantly higher in HEPA-active 
women compared to low-moderately active women, although we did not find significant 
interactions between age and physical activity levels. 
In contrast to the current study, Amrein et al. (2012) found that physically active 
adults had significantly lower sclerostin levels. This study utilized the Baecke 
Questionnaire, while the present study utilized the International Physical Activity 
Questionnaire for assessing physical activity. Although both questionnaires were 
validated, physical activity scores obtained from both questionnaires have a poor 
positive correlation (Sadeghisani et al., 2016). Differences in the quantification of 
physical activity scores could explain the disagreement between the two studies. 
Similarly, another cross-sectional study (Gaudio et al., 2010) reported that sclerostin 
levels were significantly higher in immobilized elderly women compared to a control 
group, supporting the link between sclerostin and mechanical unloading. 
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In humans, the effect of exercise on sclerostin is inconsistent among intervention 
studies, with some studies showing an increase (Zagrodna et al., 2016), decrease 
(Ardawi et al., 2012; Hinton et al., 2017) or no change (Mosti et al., 2014) in sclerostin 
levels. The present study is not a longitudinal study and utilized a self-reported physical 
activity questionnaire. The HEPA-active women had significantly higher sclerostin 
levels compared to low-moderately active women. The following possible mechanisms 
could explain the sclerostin levels in HEPA-active women in the present study: 1. total 
body BMD was significantly higher in HEPA active women, and larger total body 
skeletal mass could result in releasing more sclerostin into the general circulation; and 
2. an increase in Wnt signaling could stimulate an increase in sclerostin levels that 
provides a negative feedback signal at the basic multicellular unit so that bone 
homeostasis can be maintained (Baron et al., 2012).  
To date, only a few studies have examined the effects of exercise on serum 
DKK-1 levels. Animal model studies have reported that DKK-1 expression increased 
with sedentary behavior and decreased with long-term exercise (Bayod et al., 2014). A 
cross-sectional study of immobilized elderly women and a control group reported no 
significant difference in serum DKK-1 levels, which is in line with the current study.  
A recent intervention study reported a significant decrease in serum DKK-1 
levels after 12 weeks of strength training exercise (Kim et al., 2017).  The 
pharmacokinetics of DKK-1 in bone tissue could be different for various types of 
exercises and we measured serum sample not the bone tissue. Therefore, based on these 
results, DKK-1 responses on mechanical loading and bone homeostasis warrants further 
investigation.  
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It should be noted that in the present study we did not control the menstrual 
cycle phase while collecting blood samples. Previously, it has been reported that 
sclerostin and DKK-1 concentrations were not affected by the menstrual cycle and were 
not related with estradiol in premenopausal women (35-45 years) (Cidem et al., 2012; 
Liakou et al., 2016). Surprisingly, we found HC users had significantly lower sclerostin 
and DKK-1 levels compared to non-users. Therefore, the influence of sex hormones on 
Wnt signaling inhibitors deserves further investigation.  
There are various factors that could have influenced the results of the current 
study, such as types of assay kits (detecting polyclonal versus monoclonal antibodies of 
sclerostin/DKK-1), types of samples such as serum versus tissue, and still the specific 
dose relationship between Wnt inhibitors and bone formation is still unknown and 
current literature still lacks to establish normal reference ranges for those Wnt signaling 
inhibitors.  
Age, Physical Activity, and Areal Bone Mineral Density 
Based on animal and humans studies, it is now generally accepted that exercise 
improves bone mass and bone geometry and this effect is dependent on exercise 
intensity and duration. Physical activity during adolescence is associated with an 
increase in bone mass on the periosteal surfaces, while high impact and muscle loading 
exercise are associated with an increase in bone size. Therefore, peak bone mass, which 
is acquired during childhood and adolescence, could be the key determinant in lowering 
the risk of fracture in later life. Although peak bone mass is genetically determined, 
other determinants of peak bone mass are amenable to weight-bearing exercise and diet.   
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 A significant main effect of physical activity was detected for total body and 
spine areal bone mineral density (p<0.05) and hip areal bone mineral density variables, 
and a main effect of age was detected for spine BMC (p<0.05). The present study also 
found a significant main effect of age and physical activity levels for left trochanter 
bone mineral density. The results of the current study are in line with the previous study 
by Liang et al. (2011), who found that after a 12-month strength training intervention 
there was a significant increase in heel areal bone mineral density in premenopausal 
women.    
 Similar to the present study, Baxter-Jones et al. (2008) reported that active 
adolescent females had significantly higher BMC and total femoral neck BMD 
compared to an inactive group, suggesting that participating in physical activity 
conserves skeletal formation benefits throughout the adult phase. Similarly, 
participating in high-impact exercise lead to a significant increase in femoral neck BMD 
in the exercise group compared to the control group that reflects the positive influence 
of high-impact exercise on bone (Bailey and Brooke-Wavell, 2010). 
 Accumulating evidence suggests that high-impact exercise has a direct impact 
on bone, as the strain is generated by contractile force from the tendon to the insertion 
site on bone leading to mechanical loading (Bailey and Brooke-Wavell, 2010; Mosti et 
al., 2014). Warren et al. (2008) showed a significant decrease in femoral neck BMD in 
their control group compared to a strength training group, which suggests the 
importance of mechanical loading for skeletal structure. In line with the present study, a 
randomized control trial found an increase in BMD and BMC at the lumbar spine in the 
training group compared to the control group (Mosti et al., 2014). Systemic reviews and 
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meta-analyses by Xu et al. (2016) reported that combined-impact exercise protocols 
have more significant effects on bone compared to short-bouts of exercise.  
 Both the intensity and frequency of exercise are considered as major 
determinants of bone response. In the present study, we did not measure intensity, 
frequency or total volume of exercise. The physical activity scores were based on a self-
reported questionnaire. Although we found that total PA scores were higher in middle-
aged women compare to young women, these values were not statistically significant. 
Terefore it is not possible to conclusively determine specific exercise effects on bone in 
the current study. A previous study by Bailey and Brooke-Wavell (2010) demonstrated 
that more frequent exercise is effective for bone adaptation, while the present study 
relied on the self-reported questionnaire for current and past BPAQ score.  
Age, Physical Activity, and Volumetric Bone Mineral Density 
 In contrast to previous studies (Wilks et al., 2009; Evans et al., 2012), the 
current study did not find significant differences in bone geometry based on physical 
activity. The results showed a significant main effect of age on total volumetric BMC, 
trabecular BMC and BMD, and trabecular bone strength index at 4% tibia site (p<0.05). 
We also found a significant main effect of age at 38% cortical vBMD, 66% total area, 
periosteal circumference, and polar moment of inertia of the tibia. It is well documented 
that quantifying trabecular and cortical bone characteristics can identify the individual 
risk of fracture in later life (Hamilton et al., 2010). The results from the current study 
showed a trend that young women were taller than middle-aged women. Because 
middle-aged women were shorter, their smaller bones could be subjected to lower bone 
loading.   
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 Increased periosteal growth is a key factor for protecting against bone loss 
during aging. It has been reported that bone resorption during aging occurs at the 
endocortical surface, and periosteal apposition needs to increase close to 350% so that 
gradual bone loss at the endosteal apposition is maintained (Jepsen and Andarawis-Puri, 
2012). It has also been reported that regardless of physical activity, periosteal 
circumference increases with age (Kaji et al., 2005), which is in contrast with the 
current study.  
 The results from the current study showed a significant main effect of age on 
stress-strain index and polar moment of inertia. As mentioned in the literature, the polar 
moment of inertia reflects torsional rigidity and can better predict bone fracture than can 
non-directional geometric indicators (Augat et al., 1996), and the stress-strain index 
provides a good estimate of mechanical strength. Surprisingly, the current study showed 
that middle-aged women had significantly higher cortical vBMD at 38% tibia compared 
to young women. It has been well established that exercise primarily influences cortical 
bone parameters, particularly in cortical BMD, cortical area, and both distal and shaft 
sites (Liu-Ambrose et al., 2004 and Shedd et al., 2007). In the present cross-sectional 
study, we only measured physical activity scores, which were higher in middle-aged 
women, and although not significant could possibly have driven the result for cortical 
volumetric bone mineral density at the 38% tibia site.  
Age, Physical Activity, and Hip Structural Analysis 
In the current study, we also measured Hip Structural Analysis (HSA) 
parameters, another geometric measure and indicator of hip fracture risk at the femoral 
neck in women independent of BMD. According to Martin and Burr (1984), a one 
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standard deviation increase in HSA is associated with 1.8 fold increase in hip fracture 
risk. As mentioned previously, variations and bone strength differences that occur 
during aging are mostly geometric in nature, and accurate measurements could provide 
a proper assessment of the bone strength (Beck, 2007). The image we obtained from 
DXA is 2D but with the advancement in DXA software, we can assess bone geometry, 
which is helpful in determining fracture risk. The variables for HSA included in this 
study were SI, CSMI, SM, and BR (Faulkner et al., 2006; Bonnick, 1989; Beck, 2007, 
Roark and Young., 1989). 
 The results from the current study showed that there was a significant main 
effect of age on left SM, which is in line with Beck et al. (2000), that age is associated 
with a decline in sectional modulus at the proximal femur site. It has been reported that 
participating in high-impact exercise resulted in an increase in SM that disappears at 3.5 
years (Heinonen et al., 2012). Although we did not find a significant main effect for 
physical activity in the current study, exercise or mechanical loading is associated with 
enhancing structural strength against compressive and bending loading (Heinonen et al., 
2012). Further research on different loading modalities is necessary to understand 
skeletal geometric properties. One longitudinal study reported proximal femoral bone 
assessment with women spanning three generations including adolescence (girls), 
premenopausal (mothers) and postmenopausal women (maternal grandmothers) (Wang 
et al., 2014). They found that hip strength index decreased rapidly after menarche, 
remained constant afterward and significantly decreased after the postmenopausal stage.  
 The current study showed that there was a significant main effect of age and 
physical activity for right BR. A previous study reported that buckling ratio decreased 
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in the exercise group compared to the diet group in elderly people, which is in line with 
the current study, suggesting that mechanical loading plays an important role in elderly 
skeleton composition (Armamemento-Villareal et al., 2012) as it does in young women 
as shown in the current study. Notably, cortical thickness, lower femoral neck aBMD, 
and BR are strong predictors of cervical and trochanteric fracture, whereas CSMI and SI 
are only the determinants of trochanteric fracture (Szulc et al., 2006). One of the 
limitations of HSA is that the software could not determine periosteal and endosteal 
diameter that make difficult to explain the changes that occur in cross-sectional area 
(Wang et al., 2014). 
  Age, Physical Activity, and Muscular Function Assessment 
 The results from the current study on jump characteristics showed that, 
regardless of physical activity, there was a significant age effect for time in air, vertical 
jump height and relative jump power. There was also a significant age effect for 1RM 
muscle strength. Aging is associated with gradual loss of lean body mass and muscle 
function, including muscle power and strength (Janssen et al., 2000). Muscle power is 
considered a direct measure of muscle function and is positively associated with bone 
strength, especially in the cortical site (Hardcastle et al., 2014; Janz et al., 2015).  
 A previous cross-sectional study by Dietzel et al. (2013) reported that there was 
a 20% decline in force from the third to the ninth decade both in men and women. There 
was also 40-50% decline in power in women 40-49 years old. In contrast, the current 
study did not find any significant differences in power between two age groups; 
however, there was a significant age difference when power was expressed relative tp 
body weight (relative power).  
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 One cross-sectional study reported more than 50% decline in peak power 
specific to body mass between the ages of 20-80 years (Runge et al., 2004). The authors 
also reported a correlation between jump power with age after adjusting for body mass, 
which is similar to the current study, where we reported significant differences in 
relative jump power. We also found significantly lower 1RM strength in middle-aged 
women compared to young women. The possible mechanisms for age-related decline in 
muscle strength include decreases in the size and number of fast twitch muscle fibers. 
The decrease in sliding speed of the myosin molecule and changes in the mechanical 
properties of tendons also exert an additive effect on age-related decline in muscle 
strength (Mosti et al., 2014; Narici et al., 2003).  
 It is well established that muscle contraction provides significant strain to 
stimulate osteogenic responses. Physical activity and intrinsic muscle properties are 
important factors to increase strain, which leads to bone adaptation. In support of this 
concept, high impact exercise such as the vertical jump has proven to be effective in 
improving bone health. The muscle cross-sectional area also plays an important role in 
muscle strength; however, in the current study, we did not find significant differences in 
the muscle cross-sectional area between two age groups.  
Wnt Signaling Inhibitor Relationships with Bone Mineral Density, Hip Structural 
Analysis, and Muscle Strength Variables 
 The results from the bivariate correlations showed that both sclerostin and 
DKK-1 were weakly positively associated with spine BMD. Modder et al. (2010) and 
Sheng et al. (2011) reported that age-adjusted total body BMD, spine BMD and hip 
BMD were positively associated with sclerostin, which is in line with the current study. 
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Although the reason for this paradoxical association is still unknown, the weak positive 
relationship could be possibly due to two mechanisms; sclerostin is produced 
exclusively by osteocytes and could reflect the number of osteocytes, and increase in 
age leads to decrease in renal clearance of sclerostin.  
In the current study, HEPA-active women had significantly higher sclerostin 
levels that lead to constant bone formation, reflecting an increase in the Wnt signaling 
pathway. This could possibly increase sclerostin levels so that bone homeostasis is 
maintained through a negative feedback signal on osteoblasts. In the current study, 
DKK-1 exhinited a weak positive relationship with spine BMD, which is in contrast to 
the previous studies by Hampson et al. (2013) who reported no association, and Butler 
et al. (2011) who reported a negative association. The weak positive association 
between the spine and hip BMD with DKK-1 levels could be partly explained by 
differences in tissue distribution (Hampson et al. 2013). Another explanation could be 
that DKK-1 is produced not only by the skeleton but also other tissues such as platelets 
and vascular cells (Thambiah et al., 2012). However, one study contradicted this 
explanation by showing a correlation between circulating sclerostin levels and marrow 
plasma levels, suggesting that circulating sclerostin levels do not reflect changes in 
bone cells (Drake et al., 2010). Therefore, weak positive correlation in the current study 
merits further investigation. 
We did not find any association between sclerostin and DKK-1 levels with hip 
structural analysis variables, which is in contrast to the previous study by Armamento-
Villareal et al. (2012), who reported significant correlation among sclerostin, sectional 
modulus, and buckling ratio. The possible explanation could be due to the age group, as 
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the previous study was done in elderly individuals where the buckling ratio was higher 
than for the premenopausal women in the current study. 
There was a weak negative association for 38% cortical area, periosteal and 
endosteal circumference with sclerostin levels. However, sclerostin is moderately 
associated with cortical volumetric bone mineral density. It has been reported that 
SOST knockout mice have significantly higher cortical bone and mice with 
overexpressed SOST have thinner cortices and trabecular bone, reflecting sclerostin as a 
negative regulator in the skeleton (Li et al., 2008; Loots, et al., 2006). The moderate 
positive association might reflect osteocyte number, or could possibly difference in the 
secretion pattern in different skeletal tissue..  
The moderate positive relationship between sclerostin levels and cortical vBMD 
in the current study is in line with a previous study (Thorson et al., 2013) that reported a 
positive relationship between sclerostin at 66% tibia, suggesting 66% tibia is 
comparatively less loaded than 38% tibia. From the perspective of strength, bone 
loading is highly dependent on mechanical forces rather than just gravitational loads. 
The weak negative association with 38% tibia site raises the possibility that sclerostin 
production regulates cortical structure, as higher loading leads to less sclerostin 
production. The current study did not find any significant relationships between DKK-1 
and pQCT bone variables. In contrast to the current study, animal studies suggested that 
reduced DKK-1 expression is associated with significant increases in the proximal tibia, 
and overexpressed DKK-1 is associated with reduced proximal tibia density 
(MacDonald et al., 2007; Yao et al., 2011).  
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We also found weak negative relationships between vertical jump height and 
time in air with sclerostin levels. The previous study by Thorson et al. (2013) reported 
that sclerostin levels are negatively associated with grip strength, possibly due to 
mechanical forces caused by gravity. The inverse relationship from the current study 
suggests that changes in sclerostin levels could influence muscle activity, which could 
possibly increase serum sclerostin levels during muscle atrophy or disuse. A paradigm 
based on an animal study reported that Wnt7a signaling stimulated skeletal muscle 
growth and improved muscle strength via a non-canonical pathway through the 
activation JNK or AKT-mTOR (Bentzinger et al., 2014). However, due to lack in the 
literature, cross talk between muscle-bone and Wnt signaling pathway deserves further 
investigation. 
To our knowledge, this is the first study to examine the relationship between 
sclerostin and DKK-1 levels with pQCT parameters in young and middle-aged women. 
To date, no studies have reported sclerostin and DKK-1 responses to muscle strength. 
The findings from the current study showed sclerostin and DKK-1 are important 
modulators of bone remodeling processes. 
Although the current study had unique features, there are certain limitations. 
Since there are only a few studies of Wnt signaling inhibitors in humans, the results are 
largely explained based on the animal studies. In humans, it is not feasible to examine 
changes in osteocyte expression of sclerostin in bone. In this cross-sectional study, a 
self-reported IPAQ questionnaire was used to calculate physical activity scores, which 
could have influenced the results. Also, we did not measure bone formation, resorption, 
serum calcium, PTH, IGF-1, or serum vitamin D levels that could have prevented in-
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depth understanding of Wnt signaling inhibitors and bone characteristics in 
premenopausal women.  
The current study measured serum sclerostin concentrations ranging from 0.27 
to 0.91 ng/ml and serum DKK-1 concentrations ranging from 15.53 to 86.16 pmol/l. 
The current study utilized TECO and Eagle manufacturer kits for sclerostin and DKK-1 
assays, respectively. It has been reported that different commercially available 
sclerostin assay kits detect large differences in the sclerostin levels. Therefore, 
standardization of the assays should be done cautiously with attention to reference 
ranges to use sclerostin and DKK-1 as the diagnostic tool for measuring bone diseases 















Chapter 5: Conclusions 
The primary purpose of this study was to compare serum concentrations of 
sclerostin and DKK-1 in young (20-30 years) and middle-aged (35-45 years) 
premenopausal women. These age groups were selected to allow comparisons between 
women who are still accruing bone mass versus those who have already achieved their 
peak bone mass. The following research questions were investigated: 1. Will there be a 
significant difference in sclerostin and DKK-1 serum concentrations between two age 
groups of young (20-30 years) and middle-aged premenopausal women (35-45 years)? 
2. Will there be a significant difference in sclerostin and DKK-1 serum concentrations 
based on the physical activity status (low, moderate, and HEPA-active women)? 3. Will 
there be a significant interaction between age groups (20-30 years and 35-45 years) and 
physical activity status (low, moderate, and HEPA-active women) for sclerostin and 
DKK-1 serum concentrations?   
Hypothesis 1. Sclerostin and DKK-1 serum concentrations will be lower in young 
women (20-30 years) compared to middle-aged premenopausal women (35-45 
years). 
 Yes, findings from the current study showed sclerostin levels were significantly 
lower in young women compared to middle-aged women (p<0.001). We did not find 
significant age group differences for DKK-1 levels. 
Hypothesis 2. Women with higher physical activity levels will have lower sclerostin 
and DKK-1 serum concentrations.  
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 Findings from the current study do not support this hypothesis. Sclerostin levels 
were significantly higher in HEPA-active women compared to low-moderately active 
women (p<0.05). We did not find significant differences based on physical activity 
levels for DKK-1 concentrations. 
Hypothesis 3. There will be no interaction between age and activity level, as both 
age groups will show the same pattern for sclerostin and DKK-1 serum 
concentrations, which will decrease as physical activity level (low-moderate and 
HEPA-active) increases.  
The findings from this study showed significant main effects of age or physical 
activity only for sclerostin. There was no significant age group × physical activity status 
interaction for either sclerostin or DKK-1. 
Sub-hypothesis 1. There will be a moderate inverse relationship between sclerostin 
and DKK-1 serum concentrations and aBMD and vBMD in young and middle-
aged premenopausal women.  
This hypothesis was not supported by the findings of this study. Sclerostin 
showed a significant low positive relationship with hip aBMD variables, specifically 
right neck Z-Score, left neck Z-Score, right trochanter BMD, right trochanter Z-Score, 
left trochanter Z-score and total right BMD. DKK-1 also showed a low positive 
relationship with right and left trochanter BMD, and right and left trochanter Z-Score. 
There were no significant correlations between sclerostin and DKK-1 levels and 
hip structural analysis variables (strength index, buckling ratio, sectional modulus, and 
CSMI). There were no correlations observed for sclerostin and DKK-1 levels with 4% 
pQCT variables. There was a significant low negative correlation between sclerostin 
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and total area, periosteal circumference, and endosteal circumference, a significant low 
positive correlation for total vBMD, and a moderate positive relationship for cortical 
vBMD at 38% tibia. However, no significant correlations were observed between DKK-
1 and 38% pQCT variables. There was a significant low positive relationship between 
sclerostin and cortical vBMD at 66% tibia. However, there was no significant 
association found between DKK-1 and 66% tibia variables. 
Sub-hypothesis 2. There will be a strong inverse relationship between sclerostin 
and DKK-1 serum concentrations with jump power and leg press in young and 
middle-aged premenopausal women. 
There was significant low negative association for time in air and vertical jump 
height variables with sclerostin levels. However, DKK-1 did not show any significant 
correlation with muscle strength variables. 
Clinical Significance 
The evidence on Wnt signaling and bone formation provide critical cues for the 
treatment of skeletal disorders such as osteoporosis. Sclerostin and DKK-1 are potent 
regulators of the Wnt signaling pathway, and directly bind to Wnt ligands and degrade 
β-catenin before it translocates into the nucleus and suppresses gene transcription for 
bone formation. According to the International Osteoporosis Foundation and 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
recommendation, procollagen type I N-terminal peptide (P1NP) and C-terminal 
telopeptide of type I collagen (CTx), should be used in predicting osteoporosis 
(Vasikaran et al., 2011). Notably, these markers reflect the functions of osteoblasts and 
osteoclasts and not the osteocytes. The Wnt signaling inhibitors sclerostin and DKK-1 
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are exclusively produced and secreted by osteocytes and act as negative modulators of 
bone metabolism. Therefore, these markers could be used as fracture predictors of 
osteoporosis both in men and women. 
Sclerostin and DKK-1 provide an opportunity for developing new anabolic 
therapies, including anti-sclerostin and anti-DKK-1 antibodies that increase rapid 
fracture healing and bone mineral density. These therapies could provide a promising 
approach in treating osteoporosis and skeletal disorders. Recent results from phase three 
clinical trials for the drug romosozumab, showed a significant reduction in vertebral and 
clinical fracture in osteoporotic postmenopausal women (Cosman et al., 2016). 
Similarly, use of a bispecific antibody against sclerostin and DKK-1 has shown 
synergistic bone formation and fracture healing in mice and non-human primates 
(Florio et al., 2016). Therefore, understanding the regulation of SOST in human 
osteoblastic cell lines and epigenetic modification could be useful in identifying an 
additional target to treat bone diseases. 
Future Directions 
 As mentioned previously, sclerostin is exclusively secreted from osteocytes and 
has provided an important step in understanding the regulation of bone remodeling. 
Animal studies have reported that sclerostin and DKK-1 expression was downregulated 
in the presence of mechanical loading. Studies on different types of exercise such as 
resistance exercise, jump exercise, whole-body vibration, and endurance exercise are 
limited in humans and deserve further attention. Therefore, future research in humans 
should also include developing exercise interventions for sclerostin and DKK-1 along 
with changes in BMD and bone strength parameters in both genders with different age 
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groups and with large sample size. The measurement of Wnt signaling inhibitors is 
novel to bone research and this technology still continues to advance. Therefore, 
standardized procedures for serum assays should be incorporated so that reliable 
reference ranges of sclerostin and DKK-1 can be established. Long-term exercise 
interventions can detect changes in BMD compared to short-term studies, therefore, 
future studies should involve long-duration exercise interventions in comparing 
sclerostin and DKK-1 levels. It is widely accepted that exercise has a positive impact on 
bone, incorporating exercise responses in Wnt pathway could explore avenues in bone 
biology. Further, study on vitamin D, calcium, and parathyroid hormones analysis along 
with Wnt signaling inhibitors in intervention studies could provide knowledge in the 
biology of bone and Wnt signaling pathway.  
Sclerostin and DKK-1 are secreted at high levels during unloading conditions 
such as bed rest, and astronauts during space missions. The lack of weight-bearing 
forces exerts a negative effect on bone cells in the microgravity environment due to 
there being less mechanical strain. Microgravity induces muscle atrophy and bone loss 
that can deteriorate astronauts' health and performance. Therefore, understanding the 
role of sclerostin and DKK-1 in microgravity could contribute in developing a strategy 
for space travel and for a future human mission to Mars. 
In summary, both human and animals showed Wnt signaling as a negative 
regulator of bone mass and potential concerns regarding mode of action to enhance 
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Appendix A: Informed Consent  


























Appendix B: Questionnaires  
Health Screening, Menstural History, Calcium Intake, International Physical Activity 



















































Appendix C: Recruitment Materials 
 



























Appendix D: Precision 





























Fatfree Mass 1.74% 
Total Body BMD 0.71% 
Total  BMC 0.55% 
Spine BMD 1.45% 
Dual Femur BMD 0.67% 
Spine BMC 1.52% 
Right Neck 0.91% 
Left Neck 1.01% 
Right Trochanter 0.77% 
Left Trochanter 1.04% 
Total Left 0.68% 
Total Right 0.61% 
Right SI 4.63% 
Right Buckling Ratio 2.9% 
Right SM 2.35% 
Right CSMI 2.42% 
Left SI 5.2% 
Left Buckling Ratio 17% 
Left SM 2.33% 
Left CSMI 2.74% 
4% Total vBMC 1.19% 
4% Total vBMD  1.01% 
4% Total Area   1.86% 
4% Trab Area 1.93% 
4% Peri C  1.39% 
4% BSI  1.17% 
150 
4% Total vBMC 1.19% 
4% Total vBMD  1.01% 
4% Total Area   1.86% 
4% Trab Area 1.93% 
4% Peri C  1.39% 
4% BSI  1.17% 
4% Trab BSI 1.47% 
38% Total vBMC  0.33% 
38% Total vBMD  0.21% 
38% Total Area   0.38% 
38% Peri C  0.19% 
38% Endo C    0.35% 
38% Cort vBMC  0.36% 
38% Cort vBMD 0.20% 
38% Cort Area 0.47% 
38% SSI  0.88% 
38% IPolar  0.71% 
66% Total vBMC  0.24% 
66% Total vBMD  0.67% 
66% Total Area   0.67% 
66% Peri C  0.33% 
66% Endo C           0.74% 
66% Cort vBMC  0.34% 
66% Cort vBMD 0.25% 
66% Cort Area 0.38% 
66% SSI  0.93% 
66% IPolar  1.11% 




Appendix E: Correlation 























Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Right Strength Index 0.06 Right Strength Index 0.13 
Right Buckling Ratio -0.75 Right Buckling Ratio 0.08 
Right Sectional Modulus 0.07 Right Sectional Modulus 0.17 
Right CSMI -0.31 Right CSMI 0.19 
Left Strength Index 0.07 Left Strength Index 0.05 
Left Buckling Ratio 0.07 Left Buckling Ratio -0.15 
Left Sectional Modulus 0.04 Left Sectional Modulus 0.15 
Left CSMI 0.03 Left CSMI 0.12 
 
Variables r Variables r 
Serum sclerostin and  Serum DKK-1 and  
Total vBMC 0.03 Total BMC 0.15 
Total vBMD 0.07 Total vBMD 0.09 
Trabecular BMC -0.07 Trabecular BMC 0.02 
Trabecular vBMD -0.06 Trabecular vBMD -0.03 
Total Area -0.02 Total Area 0.12 
Trabecular Area -0.05 Trabecular Area 0.07 
Periosteal Circumference -0.00 Periosteal Circumference 0.13 
Bone Strength Index 0.06 Bone Strength Index 0.13 





Appendix F: Package Inserts 
Package Inserts for Sclerostin, DKK-1 and FSH assays 
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